<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="systematic-review" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Front Public Health</journal-id><journal-id journal-id-type="pmc-domain-id">2277</journal-id><journal-id journal-id-type="pmc-domain">frontpubhealth</journal-id><journal-id journal-id-type="publisher-id">Front. Public Health</journal-id><journal-title-group><journal-title>Frontiers in Public Health</journal-title></journal-title-group><issn pub-type="epub">2296-2565</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11319152</article-id><article-id pub-id-type="pmcid-ver">PMC11319152.1</article-id><article-id pub-id-type="pmcaid">11319152</article-id><article-id pub-id-type="pmcaiid">11319152</article-id><article-id pub-id-type="pmid">39139667</article-id><article-id pub-id-type="doi">10.3389/fpubh.2024.1367480</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Public Health</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Individual risk factors associated with SARS-CoV-2 infection during Alpha variant in high-income countries: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Moniz</surname><given-names initials="M">Marta</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2186085/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pereira</surname><given-names initials="S">Sofia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2527154/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soares</surname><given-names initials="P">Patricia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1050496/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Aguiar</surname><given-names initials="P">Pedro</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donato</surname><given-names initials="H">Helena</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/827460/overview"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Leite</surname><given-names initials="A">Andreia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1052436/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>NOVA National School of Public Health, Public Health Research Centre, Comprehensive Health Research Center, CHRC, REAL, CCAL, NOVA University Lisbon</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff><aff id="aff2"><sup>2</sup><institution>Public Health Unit, Amadora Primary Healthcare Cluster</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Epidemiology, Instituto Nacional de Sa&#250;de Doutor Ricardo Jorge (INSA)</institution>, <addr-line>Lisbon</addr-line>, <country>Portugal</country></aff><aff id="aff4"><sup>4</sup><institution>Documentation and Scientific Information Service, Centro Hospitalar e Universit&#225;rio de Coimbra</institution>, <addr-line>Coimbra</addr-line>, <country>Portugal</country></aff><author-notes><fn fn-type="edited-by" id="fn0001"><p>Edited by: Talha Bin Emran, Brown University, United States</p></fn><fn fn-type="edited-by" id="fn0002"><p>Reviewed by: Clara Mariana Gon&#231;alves Lima, State University of Campinas, Brazil</p><p>Harapan Harapan, Syiah Kuala University, Indonesia</p><p>Md Saqline Mostaq, University of Louisiana at Monroe, United States</p><p>Md Emranul Karim, Massachusetts Institute of Technology, United States</p></fn><corresp id="c001">*Correspondence: Marta Moniz, <email>martafmoniz@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>7</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">454087</issue-id><elocation-id>1367480</elocation-id><history><date date-type="received"><day>08</day><month>1</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>07</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-08-28 21:25:29.597"><day>28</day><month>08</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 Moniz, Pereira, Soares, Aguiar, Donato and Leite.</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Moniz, Pereira, Soares, Aguiar, Donato and Leite</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fpubh-12-1367480.pdf"/><abstract><sec id="sec1"><title>Objectives</title><p>This study aimed to systematically appraise risk factors associated with SARS-CoV-2 infection in high-income countries during the period of predominance of the Alpha variant (January 2020 to April 2021).</p></sec><sec id="sec2"><title>Methods</title><p>Four electronic databases were used to search observational studies. Literature search, study screening, data extraction and quality assessment were conducted by two authors independently. Meta-analyses were conducted for each risk factor, when appropriate.</p></sec><sec id="sec3"><title>Results</title><p>From 12,094 studies, 27 were included. The larger sample size was 17,288,532 participants, more women were included, and the age range was 18&#8211;117&#8201;years old. Meta-analyses identified men [Odds Ratio (OR): 1.23, 95% Confidence Interval (CI): 1.97&#8211;1.42], non-white ethnicity (OR: 1.63, 95% CI: 1.39&#8211;1.91), household number (OR: 1.08, 95% CI: 1.06&#8211;1.10), diabetes (OR: 1.22, 95% CI: 1.08&#8211;1.37), cancer (OR: 0.82, 95% CI: 0.68&#8211;0.98), cardiovascular diseases (OR: 0.92, 95% CI: 0.84&#8211;1.00), asthma (OR: 0.83, 95% CI: 0.75&#8211;0.92) and ischemic heart disease (OR: 0.82, 95% CI: 0.74&#8211;0.91) as associated with SARS-CoV-2 infection.</p></sec><sec id="sec4"><title>Conclusion</title><p>This study indicated several risk factors for SARS-CoV-2 infection. Due to the heterogeneity of the studies included, more studies are needed to understand the factors that increase the risk for SARS-CoV-2 infection.</p></sec><sec id="sec05"><title>Systematic review registration</title><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021244148" ext-link-type="uri">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021244148</ext-link>, PROSPERO registration number, CRD42021244148.</p></sec></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>infectious disease</kwd><kwd>risk-factors</kwd><kwd>systematic review</kwd><kwd>meta-analysis</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was funded by the Foundation for Science and Technology (FCT) through a PhD research scholarship (2020.09525.BD) granted under the Call DOCTORATES 4 COVID-19; and FCT (reference: CEECINST/00049/2021/CP2817/CT0001 and DOI: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://10.54499/CEECINST/00049/2021/CP2817/CT0001" ext-link-type="uri">10.54499/CEECINST/00049/2021/CP2817/CT0001</ext-link>). This study is sponsored by Pfizer (grant code #68639655; URL: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pfizer.pt/" ext-link-type="uri">https://www.pfizer.pt/</ext-link>). The funders did not have a role in study design, data collection and analysis, or the decision to publish and prepare the manuscript.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="90"/><page-count count="12"/><word-count count="9043"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Infectious Diseases: Epidemiology and Prevention</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec6"><title>Introduction</title><p>In December 2019, an atypical pneumonia outbreak was registered in the Wuhan province. The Chinese authorities later identified a new virus &#8211; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) &#8211; as the pathogen originating the outbreak. The globalized world propelled its dissemination, and in just a few months, COVID-19 reached several countries. On March 11th of 2020, the World Health Organization declared COVID-19 as a pandemic (<xref rid="ref1" ref-type="bibr">1</xref>), which on August 24th of 2022 had already infected almost 600 million people and caused over 6 million deaths globally (<xref rid="ref2" ref-type="bibr">2</xref>). Due to its utmost impact on overall human life, the United Nations Organization has declared COVID-19 a social, human, and economic crisis (<xref rid="ref3" ref-type="bibr">3</xref>).</p><p>Recognizing the rapid spread and severe impact of the pandemic, researchers have been working to understand the virus and its effects. Hence, a large volume of literature on SARS-CoV-2 infection has been published, namely epidemiological characteristics of positive cases and outcomes. Thus, leading to the development of systematic review (SR) on risk factors for developing infection, severe disease and mortality. SRs identified several factors associated with severe COVID-19, such as being older (<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>), male (<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>), having a high body mass index (<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>) and multiple previous comorbidities [e.g., hypertension, diabetes, cardiovascular disease, chronic obstructive pulmonary disease (<xref rid="ref4" ref-type="bibr">4</xref>), and active cancer (<xref rid="ref5" ref-type="bibr">5</xref>)]. Other SRs identified factors associated with SARS-CoV-2 infection, such as lack of protective personal equipment, being female, poor access to healthcare, high volume of tourism and high population density. However, SRs on risk factors for infection were mainly restricted to specific subgroups (i.e., health workers) (<xref rid="ref6" ref-type="bibr">6</xref>) or continents (i.e., Africa) (<xref rid="ref7" ref-type="bibr">7</xref>), in which factors might be different to other contexts due to specific contacts and demographics.</p><p>Furthermore, when comparing infection rates, a disparity seems to emerge between different economic contexts. High-income countries reported higher infection rates than low-income countries (<xref rid="ref8" ref-type="bibr">8</xref>), which might be partially explained by different contextual factors, medical infrastructures, and human and technical resources. There was only one SR in high-income countries, conducted in the UK, regarding risk factors for SARS-CoV-2 infection. This SR found that older adults, being male, black, having previous comorbidities, living in urban areas and more deprived areas were associated with a higher risk of SARS-CoV-2 infection. However, this search ended in early pandemic stages (April 2020) and was restricted to England and Wales (<xref rid="ref9" ref-type="bibr">9</xref>).</p><p>Additionally, the evolving understanding of risk factors revealed some unique characteristics of COVID-19. Although COVID-19 is a respiratory manifestation, evidence shows that some risk factors for SARS-CoV-2 infection are different from other infectious respiratory diseases in high-income countries, i.e., pneumonia was more common in women and COVID-19 was more common in men (<xref rid="ref10" ref-type="bibr">10</xref>). There is also contradictory evidence regarding the effect of some diseases, such as diabetes (<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>) and cancer (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>). Moreover, SARS-CoV-2 variants show different transmissibility between them depending on both characteristics of the variants and the population where it spreads, translating into different case severity (<xref rid="ref15" ref-type="bibr">15</xref>, <xref rid="ref16" ref-type="bibr">16</xref>). The Delta variant already seemed more transmissible than Alpha, i.e., showing differences in the characteristics of index cases (<xref rid="ref17" ref-type="bibr">17</xref>). In the majority of high-income countries, the Alpha variant was the most predominant variant responsible for SARS-CoV-2 epidemic surges between the end of 2020 and the first half of 2021 (<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>). Given these complexities and heterogeneity, there is a need for focused research on specific periods and contexts. Thus, given the contextual differences between high- and low-income countries and possible differences in the risk of infection according to different SARS-CoV-2 variants, we aim to systematically appraise and quantify the risk factors associated with SARS-CoV-2 infection during the period of predominance of the Alpha variant in high-income countries.</p></sec><sec sec-type="methods" id="sec7"><title>Methods</title><p>This SR protocol has been developed according to the Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) (<xref rid="ref19" ref-type="bibr">19</xref>) and reported in accordance with MOOSE (Meta-analysis Of Observational Studies in Epidemiology) guidelines (<xref rid="SM1" ref-type="supplementary-material">Supplementary File 1</xref>) (<xref rid="ref20" ref-type="bibr">20</xref>). We have registered the protocol in the International Prospective Register of Systematic Reviews (PROSPERO), registration ID number: CRD42021244148.</p><sec id="sec8"><title>Data sources and search strategy</title><p>The data sources comprised PubMed; Web of Science; EMBASE; MedRxiv, and international conferences (European Scientific Conference on Applied Infectious Disease Epidemiology, ESCAIDE) relevant for this matter, from 2020 and 2021. The World Congress on Public Health (WCPH) and the European Public Health Conference (EPHC) were also considered, but the abstracts presented in these two conferences were published, therefore appearing in the searched databases. The databases were searched from 1/1/2020 to 22/4/2021 when the Alpha variant was predominant in the majority of high-income countries (<xref rid="ref18" ref-type="bibr">18</xref>) and the last search was conducted on 31/5/2021.</p><p>Search terms (text words and Mesh terms) were drawn up for three search concepts: SARS-CoV-2, risk factors, and high-income country. The search in the conference abstract book was done using the words &#8220;COVID-19&#8221; or &#8220;SARS-CoV-2.&#8221; High-income countries were defined according to the classification from the World Bank (<xref rid="ref21" ref-type="bibr">21</xref>). The detailed search strategy is provided in <xref rid="SM1" ref-type="supplementary-material">Supplementary File 2</xref>. The literature search was performed by two authors, an investigator and a librarian (M.M. and H.D., respectively).</p></sec><sec id="sec9"><title>Inclusion and exclusion criteria</title><p>We included all Portuguese, English, French, Spanish and Italian studies that evaluated the risk factors for SARS-CoV-2 infection in high-income countries with a confirmed Polymerase chain reaction (PCR) SARS-CoV-2 positive test result on people 18&#8201;years old or more. After polling the articles and eliminating duplicates, a manual review of titles and abstracts was performed, screening for relevant topics and keywords. Similar studies, in title and authors, found in different databases were screened and confirmed to have different objectives. We excluded articles covering reinfection, specific settings and populations (e.g., health workers, schools, hospitalized patients, pregnant women and people with disabilities). We also excluded articles where diagnosis of SARS-CoV-2 infection was self-reported, or the case definition was a composite of various tests (PCR, antigen, blood samples), and suspected and/or clinically diagnosed cases. Genetic factors were also excluded due to the complexity of the analysis. Environmental factors were excluded due to their specific time&#8211;space patterns, thus challenging pooled estimates. Articles lacking information on SARS-CoV-2 infection measurement or population age were excluded for consistency. See <xref rid="fig1" ref-type="fig">Figure 1</xref> for a detailed summary of the selection process.</p><fig position="float" id="fig1" orientation="portrait"><label>Figure 1</label><caption><p>Diagram of study selection, adapted from PRISMA group 2020 flow diagram (high-income countries, 2020&#8211;2021).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpubh-12-1367480-g001.jpg"/></fig><p>All individual-based study designs were potentially eligible; however, we have decided to exclude Letters to Editors, Editorials, Comments, Opinions and Ecological studies to analyze more robust information, considering the growing volume of publications. The eligibility criteria were applied by two authors independently (M.M. and S.C.) to titles/abstracts for full-text assessment. References management and screening was carried out using the Rayyan website (<xref rid="ref22" ref-type="bibr">22</xref>).</p></sec><sec id="sec10"><title>Data extraction and quality assessment</title><p>We used a random sample (10%) to pilot the extraction form and two authors (M.M and S.C.) extracted the data. After testing, we adjusted the extraction form including more fields to characterize the studies, namely sample description and controlling factors. Thus, data was extracted using a standardized form which included first author, title, year of publication, study design, study location and duration, study population, data source, sample size, sample description (age and sex), factors identified, estimated measure of effect, and control factors for the statistical analysis. Sample description was deemed important for comparison between studies.</p><p>Quality assessment of the studies was conducted by the same two authors using the Joanna Briggs Institute tool for analytical cross-sectional studies (<xref rid="ref23" ref-type="bibr">23</xref>) and Newcastle-Ottawa Scale (NOS) for case&#8211;control and cohort studies (<xref rid="ref24" ref-type="bibr">24</xref>). Since there is no universal criterion for high-quality studies, we considered those scoring &#8805;7 as high-quality, a cut-off commonly used in the literature (<xref rid="ref25" ref-type="bibr">25</xref>). Conflicts between raters in classifying individual items of the abovementioned tools were resolved by discussion with a third author (A.L.).</p></sec><sec id="sec11"><title>Data analysis</title><p>For each study, we undertook a descriptive characterization. When at least two studies reported an exposure in a consistent way (same reference and categories), these were combined in a meta-analysis (<xref rid="ref26" ref-type="bibr">26</xref>, <xref rid="ref27" ref-type="bibr">27</xref>). To obtain pooled estimates of SARS-CoV-2 infection risk factors while improving results comparability, we chose to include a single effect measure, decided as the most often reported. In studies that reported several multivariable-adjusted effect estimates, we selected the one that adjusted for more potential confounders (<xref rid="ref26" ref-type="bibr">26&#8211;28</xref>). Each study was weighted in the meta-analysis using the inverse variance of the effect estimate (<xref rid="ref29" ref-type="bibr">29</xref>).</p><p>Heterogeneity between estimates was assessed using the <italic toggle="yes">I</italic><sup>2</sup> statistic, with higher values reflecting increased heterogeneity. For higher heterogeneity coefficients (<italic toggle="yes">I</italic><sup>2</sup>) with statistically significant tests rejecting homogeneity, we used a random-effects model; otherwise, we chose a fixed-effects model (<xref rid="ref30" ref-type="bibr">30</xref>). We performed sensitivity analyses for ethnicity, diabetes and comorbidities, giving greater depth to the analysis, since they contained various categories within, susceptibly for SARS-CoV-2 infection might be misled. We performed two sensitivity analyses for ethnicity: without the category &#8220;other&#8221; and dividing the variable into the three ethnicities described (Black, Hispanic and Asian). Comorbidities were arranged into groups of diseases: respiratory diseases (asthma, COPD &#8211; chronic obstructive pulmonary disease, respiratory diseases), cardiovascular diseases (arrhythmia, heart failure, cardiomyopathy, ischemic heart disease, cardiovascular diseases), neurological diseases (Alzheimer, degenerative diseases, Parkinson, Parkinsonism and movement disorders, dementia, stroke and transient cerebral ischemia, cerebral hemorrhage) and autoimmune diseases (rheumatoid arthritis, autoimmune diseases). For diabetes we performed an analysis with the studies that analyzed the same type of diabetes. Publication bias was assessed by visually inspecting funnel plots. Statistical analyses were conducted in SPSS version 28.0.1.0 (<xref rid="ref31" ref-type="bibr">31</xref>).</p></sec></sec><sec sec-type="results" id="sec12"><title>Results</title><p>The search strategy identified 13,859 records. After removing the duplicates, 12,094 records were screened for title and abstract and full-text screening was performed in the 164 remaining records, from which 27 met the inclusion criteria and were included in this systematic review. An abstract from the ESCAIDE 2021 workbook was identified but excluded, as we tried to obtain more information from the authors but did not get any answer (<xref rid="fig1" ref-type="fig">Figure 1</xref>).</p><p>From the 27 studies, most studies were cohort (48.1%) (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref32" ref-type="bibr">32&#8211;43</xref>), followed by case&#8211;control (29.6%) (<xref rid="ref44" ref-type="bibr">44&#8211;51</xref>) and cross-sectional (22.2%) (<xref rid="ref52" ref-type="bibr">52&#8211;57</xref>) studies. Most studies were set in Europe (44.4%) (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref32" ref-type="bibr">32&#8211;34</xref>, <xref rid="ref36" ref-type="bibr">36</xref>, <xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref41" ref-type="bibr">41&#8211;43</xref>, <xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref47" ref-type="bibr">47</xref>, <xref rid="ref50" ref-type="bibr">50</xref>), followed by North America (29.6%) (<xref rid="ref35" ref-type="bibr">35</xref>, <xref rid="ref38" ref-type="bibr">38</xref>, <xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref45" ref-type="bibr">45</xref>, <xref rid="ref49" ref-type="bibr">49</xref>, <xref rid="ref53" ref-type="bibr">53&#8211;56</xref>) and Asia (25.9%) (<xref rid="ref40" ref-type="bibr">40</xref>, <xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref48" ref-type="bibr">48</xref>, <xref rid="ref51" ref-type="bibr">51</xref>, <xref rid="ref52" ref-type="bibr">52</xref>, <xref rid="ref57" ref-type="bibr">57</xref>). Sample size was heterogenous, ranging from 310 (<xref rid="ref43" ref-type="bibr">43</xref>) to 17,288,532 (<xref rid="ref37" ref-type="bibr">37</xref>) individuals. Participants age varied widely (range: 18&#8211;117&#8201;years old), with the majority of participants being mostly females (70.4%) (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref32" ref-type="bibr">32&#8211;35</xref>, <xref rid="ref39" ref-type="bibr">39&#8211;42</xref>, <xref rid="ref45" ref-type="bibr">45</xref>, <xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref48" ref-type="bibr">48&#8211;57</xref>). The odds-ratio (OR) was the effect measure most often used (81.5%) (<xref rid="ref32" ref-type="bibr">32</xref>, <xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref36" ref-type="bibr">36</xref>, <xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref39" ref-type="bibr">39&#8211;57</xref>), followed by risk ratio (7.4%) (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref34" ref-type="bibr">34</xref>), hazard ratio (3.7%) (<xref rid="ref33" ref-type="bibr">33</xref>) and median difference (3.7%) (<xref rid="ref35" ref-type="bibr">35</xref>). One study did not report a measure of effect, and only reported the <italic toggle="yes">p</italic>-value from the <italic toggle="yes">&#967;</italic><sup>2</sup> test and Fisher&#8217;s exact test to evaluate the differences between positive and negative cases of SARS-CoV-2 infection (<xref rid="ref38" ref-type="bibr">38</xref>).</p><p>Education was the only factor that demonstrated consistent results in the studies in which it was reported, with lower levels of education indicating a greater risk of SARS-CoV-2 infection (<xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref50" ref-type="bibr">50</xref>). Income was measured both with Social Deprivation Index (TSDI) (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref45" ref-type="bibr">45</xref>) or household income (<xref rid="ref50" ref-type="bibr">50</xref>, <xref rid="ref56" ref-type="bibr">56</xref>) and both approaches found that a lower economic level was associated with a higher risk of infection. Two studies reported alcohol drinking history, one did not show any association with infection risk (<xref rid="ref45" ref-type="bibr">45</xref>) and the other found an association with negative test (<xref rid="ref50" ref-type="bibr">50</xref>). Smoking history was reported in seven studies, being one of them related to the influence of early factors in the risk of infection, demonstrating that maternal smoking around birth was associated with a higher risk of SARS-CoV-2 infection (<xref rid="ref32" ref-type="bibr">32</xref>). Smoking history was associated with a higher risk of infection in two studies (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref38" ref-type="bibr">38</xref>) and two others reported a negative association (<xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref53" ref-type="bibr">53</xref>). The remaining studies did not show any association (<xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref50" ref-type="bibr">50</xref>).</p><p>Other risk factors were more frequently reported, such as sex (55.5%), ethnicity (44.4%), age (40.7%), economic conditions (25.9%), household conditions (14.8%) and comorbidities (51.9%), with cancer/malignancy and hypertension being the most prevalent.</p><p>Despite being reported more than once, for some risk factors [smoking status (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref33" ref-type="bibr">33</xref>, <xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref38" ref-type="bibr">38</xref>, <xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref53" ref-type="bibr">53</xref>), education (<xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref50" ref-type="bibr">50</xref>), alcohol drinking status (<xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref40" ref-type="bibr">40</xref>, <xref rid="ref45" ref-type="bibr">45</xref>, <xref rid="ref50" ref-type="bibr">50</xref>), and economic conditions (<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref45" ref-type="bibr">45</xref>, <xref rid="ref50" ref-type="bibr">50</xref>, <xref rid="ref56" ref-type="bibr">56</xref>)], it was not possible to conduct a meta-analysis or include all the studies in a single meta-analysis due to different variable categories or different variable types (continuous/categorical), and/or different effect measures.</p><p>For insurance (<xref rid="ref52" ref-type="bibr">52</xref>, <xref rid="ref54" ref-type="bibr">54</xref>) and age (<xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref46" ref-type="bibr">46</xref>, <xref rid="ref49" ref-type="bibr">49</xref>, <xref rid="ref50" ref-type="bibr">50</xref>, <xref rid="ref53" ref-type="bibr">53</xref>), only a fraction of the studies was combined due to different classifications. Age was reported as continuous or categorical, and for the meta-analysis, we extracted the measure of effect for continuous measurement since it was the type most often reported. From the studies that reported age as a continuous variable, one was not included since the confidence interval was not available, thus we lacked information to perform the meta-analysis (<xref rid="ref53" ref-type="bibr">53</xref>).</p><p>Sex was the only variable reported consistently among all the studies identified, thus, the meta-analysis for sex included all the studies reporting sex. <xref rid="tab1" ref-type="table">Table 1</xref> summarizes the key characteristics of the studies included, while more detailed information is available in <xref rid="SM1" ref-type="supplementary-material">Supplementary File 3</xref>.</p><table-wrap position="float" id="tab1" orientation="portrait"><label>Table 1</label><caption><p>Summary of the included studies considering risk factors for SARS-CoV-2 infection, <italic toggle="yes">N</italic>&#8201;=&#8201;27 (high-income countries, 2020&#8211;2021).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">First author</th><th align="left" valign="top" rowspan="1" colspan="1">Study design</th><th align="left" valign="top" rowspan="1" colspan="1">Location</th><th align="left" valign="top" rowspan="1" colspan="1">Duration</th><th align="left" valign="top" rowspan="1" colspan="1">Data source</th><th align="left" valign="top" rowspan="1" colspan="1">Sample size</th><th align="left" valign="top" rowspan="1" colspan="1">Factors identified</th><th align="left" valign="top" rowspan="1" colspan="1">Quality assessment</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Altug Didikoglu, 2021 (<xref rid="ref32" ref-type="bibr">32</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">England, United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;21 December 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">43,428</td><td align="left" valign="middle" rowspan="1" colspan="1">Early life factors</td><td align="center" valign="middle" rowspan="1" colspan="1">5/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Angel Vila-C&#243;rcoles, 2020 (<xref rid="ref33" ref-type="bibr">33</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">Tarragona, Spain</td><td align="left" valign="middle" rowspan="1" colspan="1">1 March 2020&#8211;23 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; CAPAMIS Research</td><td align="center" valign="middle" rowspan="1" colspan="1">79,083</td><td align="left" valign="middle" rowspan="1" colspan="1">Underlying comorbidities or using chronic medications</td><td align="center" valign="middle" rowspan="1" colspan="1">8/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ariel Israel, 2020 (<xref rid="ref44" ref-type="bibr">44</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">Israel</td><td align="left" valign="middle" rowspan="1" colspan="1">Beginning of the disease outbreak &#8211; 16 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; Clalit Health Services</td><td align="center" valign="middle" rowspan="1" colspan="1">24,906</td><td align="left" valign="middle" rowspan="1" colspan="1">Smoking habits</td><td align="center" valign="middle" rowspan="1" colspan="1">8/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Bing Zhang, 2021 (<xref rid="ref45" ref-type="bibr">45</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">California, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">1 March 2020&#8211;10 June 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; University of California Health system</td><td align="center" valign="middle" rowspan="1" colspan="1">861</td><td align="left" valign="middle" rowspan="1" colspan="1">Use of chronic acid suppressors</td><td align="center" valign="middle" rowspan="1" colspan="1">7/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Claire L. Niedzwiedz, 2020 (<xref rid="ref34" ref-type="bibr">34</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">England, United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;3 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">392,116</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethnicity and socioeconomic position</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ehab Hamed, 2020 (<xref rid="ref57" ref-type="bibr">57</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="middle" rowspan="1" colspan="1">Qatar</td><td align="left" valign="middle" rowspan="1" colspan="1">10 February 2020&#8211;30 April 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; publicly funded primary health care settings in the state of Qatar</td><td align="center" valign="middle" rowspan="1" colspan="1">962</td><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis of hematological abnormalities</td><td align="center" valign="middle" rowspan="1" colspan="1">6/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Eyrun F. Kjetland, 2020 (<xref rid="ref46" ref-type="bibr">46</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">Norway</td><td align="left" valign="middle" rowspan="1" colspan="1">1 January 2020&#8211;6 April 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic records &#8211; Oslo University Hospital; Online survey</td><td align="center" valign="middle" rowspan="1" colspan="1">116,678</td><td align="left" valign="middle" rowspan="1" colspan="1">Demographic, social, health risk and environmental factors</td><td align="center" valign="middle" rowspan="1" colspan="1">5/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Farhaan S. Vahidy, 2020 (<xref rid="ref56" ref-type="bibr">56</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="middle" rowspan="1" colspan="1">Houston, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">5 March 2020&#8211;31 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; Houston Methodist</td><td align="center" valign="middle" rowspan="1" colspan="1">20,228</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethnicity and race</td><td align="center" valign="middle" rowspan="1" colspan="1">5/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Farhaan S. Vahidy, 2021 (<xref rid="ref55" ref-type="bibr">55</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="middle" rowspan="1" colspan="1">Houston, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">6 March 2020&#8211;22 August 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; Houston Methodist</td><td align="center" valign="middle" rowspan="1" colspan="1">96,473</td><td align="left" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">6/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Frederick K Ho, 2020 (<xref rid="ref10" ref-type="bibr">10</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">England, United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;3 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">1,525</td><td align="left" valign="middle" rowspan="1" colspan="1">Demographic, lifestyle, socioeconomic and clinical risk factors</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Giuseppe Mancia, 2020 (<xref rid="ref47" ref-type="bibr">47</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">Lombardy, Italy</td><td align="left" valign="middle" rowspan="1" colspan="1">21 February 2020&#8211;11 March 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Databases &#8211; Lombardy Regional Health Service</td><td align="center" valign="middle" rowspan="1" colspan="1">37,031</td><td align="left" valign="middle" rowspan="1" colspan="1">Use of angiotensin-receptor blockers (ARBs) and angiotensin-converting&#8211;enzyme (ACE) inhibitors</td><td align="center" valign="middle" rowspan="1" colspan="1">7/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Harmony R. Reynolds, 2020 (<xref rid="ref35" ref-type="bibr">35</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">New York, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">1 March 2020&#8211;15 April 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; New York University (NYU) Langone Health</td><td align="center" valign="middle" rowspan="1" colspan="1">12,594</td><td align="left" valign="middle" rowspan="1" colspan="1">Use of renin-angiotensin-aldosterone system inhibitors</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Jeongkuk Seo, 2020 (<xref rid="ref58" ref-type="bibr">58</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">South Korea</td><td align="left" valign="middle" rowspan="1" colspan="1">Beginning of the disease outbreak &#8211; 15 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; South Korea Health Insurance Review and Assessment Service</td><td align="center" valign="middle" rowspan="1" colspan="1">4,932</td><td align="left" valign="middle" rowspan="1" colspan="1">Use of renin-angiotensin-aldosterone system inhibitors</td><td align="center" valign="middle" rowspan="1" colspan="1">7/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Jose L. Pablos, 2020 (<xref rid="ref36" ref-type="bibr">36</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">Spain</td><td align="left" valign="middle" rowspan="1" colspan="1">7 April 2020&#8211;17 April 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; public Research network for the Investigation of Inflammation and Rheumatic Diseases (RIER)</td><td align="center" valign="middle" rowspan="1" colspan="1">29,931</td><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis of chronic inflammatory and autoimmune rheumatic disease</td><td align="center" valign="middle" rowspan="1" colspan="1">5/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Kuan-Han H. Wu, 2021 (<xref rid="ref49" ref-type="bibr">49</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">Michigan, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">1 March 2020&#8211;29 July 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Michigan Medicine biorepository; Online survey</td><td align="center" valign="middle" rowspan="1" colspan="1">8,041</td><td align="left" valign="middle" rowspan="1" colspan="1">Demographic, lifestyle, socioeconomic and clinical risk factors</td><td align="center" valign="middle" rowspan="1" colspan="1">5/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">L. Silvia Mu&#241;oz-Price, 2020 (<xref rid="ref54" ref-type="bibr">54</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="middle" rowspan="1" colspan="1">Milwaukee, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">12 March 2020&#8211;31 March 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; Froedtert and the Medical College of Wisconsin</td><td align="center" valign="middle" rowspan="1" colspan="1">2,595</td><td align="left" valign="middle" rowspan="1" colspan="1">Race</td><td align="center" valign="middle" rowspan="1" colspan="1">8/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Leonard E Egede, 2020 (<xref rid="ref53" ref-type="bibr">53</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="middle" rowspan="1" colspan="1">Wisconsin, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">1 March 2020&#8211;10 July 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; Froedtert and the Medical College of Wisconsin</td><td align="center" valign="middle" rowspan="1" colspan="1">31,549</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethnicity and race</td><td align="center" valign="middle" rowspan="1" colspan="1">8/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Marc Chadeau-Hyam, 2020 (<xref rid="ref50" ref-type="bibr">50</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">England, United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;18 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">4,509</td><td align="left" valign="middle" rowspan="1" colspan="1">Demographic, social, health risk, medical and environmental factors</td><td align="center" valign="middle" rowspan="1" colspan="1">6/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Rohini Mathur, 2021 (<xref rid="ref37" ref-type="bibr">37</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">England, United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">1 February 2020&#8211;3 August 2020; 1 September 2020&#8211;31 December 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; OpenSAFELY platform</td><td align="center" valign="middle" rowspan="1" colspan="1">17,288,532</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethnicity</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sachin J Shah, 2020 (<xref rid="ref38" ref-type="bibr">38</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">San Francisco, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">3 February 2020&#8211;31 March 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; University of California, San Francisco</td><td align="center" valign="middle" rowspan="1" colspan="1">316</td><td align="left" valign="middle" rowspan="1" colspan="1">Demographic and medical and factors</td><td align="center" valign="middle" rowspan="1" colspan="1">5/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sara J. Cromer, 2020 (<xref rid="ref39" ref-type="bibr">39</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">New England, United States of America</td><td align="left" valign="middle" rowspan="1" colspan="1">1 February 2020&#8211;21 June 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Electronic health records &#8211; Mass General Brigham</td><td align="center" valign="middle" rowspan="1" colspan="1">57,865</td><td align="left" valign="middle" rowspan="1" colspan="1">Demographic risk factors</td><td align="center" valign="middle" rowspan="1" colspan="1">8/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Seon Cheol Park, 2021 (<xref rid="ref52" ref-type="bibr">52</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cross-sectional</td><td align="left" valign="middle" rowspan="1" colspan="1">South Korea</td><td align="left" valign="middle" rowspan="1" colspan="1">3 January 2020&#8211;31 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; South Korea Health Insurance Review and Assessment Service</td><td align="center" valign="middle" rowspan="1" colspan="1">219,729</td><td align="left" valign="middle" rowspan="1" colspan="1">Underlying comorbidities</td><td align="center" valign="middle" rowspan="1" colspan="1">6/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Seung Won Lee, 2020 (<xref rid="ref40" ref-type="bibr">40</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">South Korea</td><td align="left" valign="middle" rowspan="1" colspan="1">1 January 2020&#8211;15 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; South Korea Health Insurance Review and Assessment Service</td><td align="center" valign="middle" rowspan="1" colspan="1">216,418</td><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis of mental illness</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Wonjun Ji, 2020 (<xref rid="ref51" ref-type="bibr">51</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Case&#8211;control</td><td align="left" valign="middle" rowspan="1" colspan="1">South Korea</td><td align="left" valign="middle" rowspan="1" colspan="1">Beginning of the disease outbreak &#8211; 15 May 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; South Korea Health Insurance Review and Assessment Service</td><td align="center" valign="middle" rowspan="1" colspan="1">219,961</td><td align="left" valign="middle" rowspan="1" colspan="1">Underlying comorbidities</td><td align="center" valign="middle" rowspan="1" colspan="1">7/9</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Xiude Fan, 2021 (<xref rid="ref41" ref-type="bibr">41</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;29 June 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">9,469</td><td align="left" valign="middle" rowspan="1" colspan="1">Use of acid- suppressants</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Yizhou Yu, 2021 (<xref rid="ref42" ref-type="bibr">42</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;26 July 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">13,338</td><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis of dementia, Alzheimer disease or Parkinson disease</td><td align="center" valign="middle" rowspan="1" colspan="1">7/8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Zahra Raisi-Estabragh, 2021 (<xref rid="ref43" ref-type="bibr">43</xref>)</td><td align="left" valign="middle" rowspan="1" colspan="1">Cohort</td><td align="left" valign="middle" rowspan="1" colspan="1">England, United Kingdom</td><td align="left" valign="middle" rowspan="1" colspan="1">16 March 2020&#8211;22 August 2020</td><td align="left" valign="middle" rowspan="1" colspan="1">Database &#8211; UK Biobank</td><td align="center" valign="middle" rowspan="1" colspan="1">310</td><td align="left" valign="middle" rowspan="1" colspan="1">Baseline cardiovascular magnetic resonance (CMR) phenotypes</td><td align="center" valign="middle" rowspan="1" colspan="1">5/8</td></tr></tbody></table></table-wrap><sec id="sec13"><title>Quality assessment</title><p>Most cohort studies were rated 7 or 8 out of 8 points, mainly lacking representativeness of the exposed cohort or comparability at the baseline; most case&#8211;control studies were rated 8 out of 9 points lacking mostly representativeness of cases or with different methods of ascertainment of exposure for cases and controls; and cross-sectional studies were rated 6 out of 8 with the most common gaps being related to the identification and analysis of confounding factors. The full quality assessment of all included studies is in <xref rid="SM1" ref-type="supplementary-material">Supplementary File 4</xref>.</p></sec><sec id="sec14"><title>Meta-analysis</title><p>We conducted a meta-analysis for 21 risk factors (<xref rid="fig2" ref-type="fig">Figure 2</xref>, detailed results in <xref rid="SM1" ref-type="supplementary-material">Supplementary File 5</xref>). Two of the factors were continuous variables: age and household number. Most were categorical variables. For sex and ethnicity, the reference was female and white, respectively. The remaining variables were classified as yes or no, presence or absence. In these cases, the reference was no/absence. The variables in this situation were: health worker, insurance, asthma, obesity, diabetes, hypertension, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), Alzheimer, dementia, chronic obstructive pulmonary disease (COPD), arrhythmia, ischemic heart disease, heart failure, liver cirrhosis, rheumatoid arthritis, cancer, cerebrovascular, respiratory and cardiovascular diseases. Variable cancer includes any diagnosis of cancer, and variable cerebrovascular diseases include stroke, transient cerebral ischemia and cerebral hemorrhages. The diseases included in each group are in <xref rid="SM1" ref-type="supplementary-material">Supplementary File 6</xref>.</p><fig position="float" id="fig2" orientation="portrait"><label>Figure 2</label><caption><p>Pooled analysis of the risk factors for SARS-CoV-2 infection (high-income countries, 2020&#8211;2021). *reference: no; **reference: white.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpubh-12-1367480-g002.jpg"/></fig><p>Being a man (OR: 1.23, 95% CI: 1.97&#8211;1.42), of non-white ethnicity (OR: 1.63, 95% CI: 1.39&#8211;1.91), increasing household number (OR: 1.08, 95% CI: 1.06&#8211;1.10), or having diabetes (OR: 1.22, 95% CI: 1.08&#8211;1.37), were associated with an increased odds of getting SARS-CoV-2 infection. In contrast, having asthma (OR: 0.83, 95% CI: 0.75&#8211;0.92), ischemic heart disease (OR: 0.82, 95% CI: 0.74&#8211;0.91), cancer (OR: 0.82, 95% CI: 0.68&#8211;0.98), or cardiovascular diseases (OR: 0.92, 95% CI: 0.84&#8211;1.00) were associated with a decreased odds for the infection.</p><p>The sensitivity analysis for ethnicity without the category &#8220;Other&#8221; yielded results almost identical to the main analysis (OR: 1.70, 95% CI: 1.40&#8211;2.07). Comparing different ethnicities, Hispanics had a higher OR for SARS-CoV-2 infection (OR: 2.37, 95% CI: 1.86&#8211;3.01), followed by Black people (OR: 1.74, 95% CI: 1.18&#8211;2.57) and Asians (OR: 1.53, 95% CI: 1.21&#8211;1.95). The sensitivity analysis for type II diabetes yielded different results (OR: 1.08, 95% CI: 0.77&#8211;1.50) from the main analysis, not being a significant factor for the risk of infection. None of the sensitivity analyses for comorbidities were statistically significant.</p><p>All funnel plots suggested eventual publication bias, which is expected in a meta-analysis with observational studies (<xref rid="ref59" ref-type="bibr">59</xref>).</p></sec></sec><sec sec-type="discussion" id="sec15"><title>Discussion</title><p>This review aimed to synthesize the available evidence on risk factors associated with SARS-CoV-2 infection in high-income countries and quantify them. The high infection rate in high-income countries and the contradictory evidence found for some underlying diseases motivated this SR. Sex, ethnicity, household number and diabetes were associated with an increased risk of SARS-CoV-2 infection and asthma, ischemic heart disease, cancer and cardiovascular disease were associated with a decreased odds of infection.</p><p>Men showed a higher likelihood of becoming infected with SARS-CoV-2. This is consistent with records from other countries and meta-analyses related to SARS-CoV-2 infection (<xref rid="ref60" ref-type="bibr">60</xref>, <xref rid="ref61" ref-type="bibr">61</xref>) and susceptibility trends for other respiratory viruses (<xref rid="ref62" ref-type="bibr">62</xref>). Other studies suggest that this difference might be caused by biological and immune differences between females and males (<xref rid="ref63" ref-type="bibr">63&#8211;65</xref>), namely neurological manifestations (<xref rid="ref66" ref-type="bibr">66</xref>). Although there are several explanations for sex variations, the most common reason seems to be gender roles (<xref rid="ref60" ref-type="bibr">60</xref>). A SR that specifically analyzed sex differences in COVID-19 (pooled prevalence men: 55.0, 51.4&#8211;56.6, <italic toggle="yes">I</italic><sup>2</sup> =&#8201;99.5%) states the differences found were due to the role and behaviors of men and women in the society (<xref rid="ref60" ref-type="bibr">60</xref>). Detailing, more men are working in essential sectors and occupations that require them to continue being active, to work outside their homes and interact with other people even during lockdowns (e.g., manufacturing and sales, agriculture, food production and distribution, transportation, and security) (<xref rid="ref60" ref-type="bibr">60</xref>). An independent initiative, to promote gender equality in health, stated that the number of cases between men and women vary with age and stay apparently balanced (<xref rid="ref67" ref-type="bibr">67</xref>). This can support the behavior&#8217;s theory, as occupational issues also become less significant as people age. It is important to note that this report includes worldwide data, and the number of cases depends directly on the availability of tests. Data on testing disaggregated by sex is only available from a small number of countries, which makes it difficult to know if the case numbers suffer from ascertainment bias (<xref rid="ref67" ref-type="bibr">67</xref>). This is also true for other respiratory viruses, like influenza, where it is difficult to ascertain the precise number of cases worldwide, for which a laboratory test is also necessary to confirm the disease, and because there is also insufficient data from less developed countries (<xref rid="ref62" ref-type="bibr">62</xref>). Further studies are required to address underlying factors explaining such differences.</p><p>Non-white individuals also showed higher odds of getting infected, particularly Hispanic. Health determinants could explain this result, as ethnic minorities are commonly at the lower socioeconomic levels. Consequently, these populations tend to be over-represented in essential jobs with more contact with the public, living in worse neighborhoods or overcrowded houses, increasing the infection risk (<xref rid="ref68" ref-type="bibr">68</xref>). This trend was consistent with literature from other studies, mainly from the United States of America and the United Kingdom (<xref rid="ref69" ref-type="bibr">69</xref>). However, these results should be interpreted with caution because they are mainly from only two countries whose results might be specific to its social context (<xref rid="ref70" ref-type="bibr">70</xref>). It is worth mentioning that studies often include a category &#8220;other,&#8221; not described in detail, which makes interpreting the results challenging since we cannot know which ethnicities are included (<xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref50" ref-type="bibr">50</xref>, <xref rid="ref53" ref-type="bibr">53</xref>, <xref rid="ref56" ref-type="bibr">56</xref>). Nevertheless, our results add to the body of literature in this area.</p><p>We have identified several studies assessing pre-existing conditions with distinct results in our meta-analyses (<xref rid="ref36" ref-type="bibr">36</xref>, <xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref44" ref-type="bibr">44</xref>, <xref rid="ref45" ref-type="bibr">45</xref>, <xref rid="ref47" ref-type="bibr">47</xref>, <xref rid="ref49" ref-type="bibr">49&#8211;52</xref>, <xref rid="ref56" ref-type="bibr">56</xref>). From all the comorbidities analyzed, having a diabetes diagnosis was the only one with a higher chance of SARS-CoV-2 infection. A meta-analysis found that diabetes was the second most prevalent comorbidity in SARS-CoV-2 infected patients (9.7, 95% CI: 7.2&#8211;12.2%) (<xref rid="ref71" ref-type="bibr">71</xref>). This disease could affect the immune system and weaken the immune response against SARS-CoV-2 infection (<xref rid="ref72" ref-type="bibr">72</xref>) which is also affected by the nutritional uptake that is influenced by diabetes (<xref rid="ref73" ref-type="bibr">73</xref>). Having asthma was identified as having lower odds of SARS-CoV-2 infection. An earlier literature review focused on the influence of this comorbidity in SARS-CoV-2 infection found no association between asthma and SARS-CoV-2 infection (<xref rid="ref74" ref-type="bibr">74</xref>). This finding could suggest corticosteroids and bronchodilators, treatments for respiratory diseases, may reduce SARS-CoV-2 infection risk or reduce symptoms development leading to diagnosis (<xref rid="ref75" ref-type="bibr">75</xref>). However, this has contrasting evidence (<xref rid="ref76" ref-type="bibr">76</xref>, <xref rid="ref77" ref-type="bibr">77</xref>), being at the moment unclear the benefits and harms of respiratory disease treatments to the risk of COVID-19 infection.</p><p>Having a cancer diagnosis or a cardiovascular disease also showed lower odds for SARS-CoV-2 infection. However, there is evidence that cardiovascular diseases are important risk factors for respiratory viruses (<xref rid="ref78" ref-type="bibr">78</xref>). Specifically related to cancer, there is evidence mentioning the weakened immune system of these patients (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref79" ref-type="bibr">79</xref>), and that regular visits to healthcare facilities for therapy may expose them to the virus (<xref rid="ref80" ref-type="bibr">80</xref>). The high heterogeneity found between studies could be a reason for the apparent contradictory effect related to comorbidities.</p><p>Of the five comorbidities that showed significative ORs, four had protective results. To the best of our knowledge there is no underlying biological mechanism that explains this. Thus, similar to other studies, we hypothesize that these findings might be related to the evidence that people with comorbidities are more cautious toward their health, being more likely to avoid social gatherings, wear masks in situations where distancing is not an option and adhere to lockdown measures, possibly because they perceive their risk of being infected with SARS-CoV-2 as higher (<xref rid="ref81" ref-type="bibr">81</xref>). That is, individuals with underlying conditions are unlikely to be less prone to SARS-CoV-2 infection, but their risk can be lowered through protective behaviors. Additionally, for asthma, our meta-analysis was performed with only two studies, where asthma was present in 21% (<xref rid="ref52" ref-type="bibr">52</xref>) and 4% (<xref rid="ref44" ref-type="bibr">44</xref>) of SARS-CoV-2 cases. However, more evidence is needed to ascertain the effect of the aforementioned comorbidities on SARS-CoV-2 infection risk.</p><p>Antihypertensors, namely ACE and ARB, were not significantly associated with SARS-CoV-2 infection, as other meta-analyses also indicate (<xref rid="ref82" ref-type="bibr">82</xref>, <xref rid="ref83" ref-type="bibr">83</xref>). One of these studies analyzed the combined effect of these two medications (OR: 0.95, 95% CI: 0.89&#8211;1.02), showing that there is no evidence that this medication significantly increases the risk of infection (<xref rid="ref83" ref-type="bibr">83</xref>). These results might be associated with SARS-CoV-2 transmission dynamics, which is mainly transmitted through the respiratory tract ACE2 receptors. There is no evidence to date reporting the expression of ACE2 receptors in lung tissue after ACEI/ARB treatment (<xref rid="ref83" ref-type="bibr">83</xref>). This suggested reduction could not be confirmed in our analysis, which only included two articles for this variable.</p><p>Other risk factors, such as income, education, smoking status and drinking status, were reported in the included studies, but meta-analyses could not be performed due to heterogeneity of classification and analysis. These challenges understanding who has a higher risk of getting infected and what behaviors contribute to a higher risk of infection. Furthermore, the aforementioned factors had contradictory results in the individual studies that reported them, confirming the heterogeneity that could result in confusing guidelines to control the spreading and infection rate. In future studies on individual risk factors for SARS-CoV-2 infection, authors should analyze the variables more consistently, considering the published literature on the subject. For example, in one study, education was analyzed according to specific levels from the UK education system (<xref rid="ref42" ref-type="bibr">42</xref>), challenging comparison with other international results. Additionally, it would be important for authors to provide more detailed information, as previously pointed out, in improving reporting initiatives (<xref rid="ref84" ref-type="bibr">84</xref>).</p><p>Contextual factors could also have an important association with SARS-CoV-2 risk. However, since we excluded ecological studies, we only analyzed sociodemographic and behavioral factors. Although individual factors are important, the effect of contextual factors should also be assessed, i.e., where individuals live and/or work, type of transportation they use, and their access to health services. We urge authors to consider both factors in future analyses since analyzing them jointly strengthens SARS-CoV-2 research, providing a more comprehensive understanding of this disease (<xref rid="ref85" ref-type="bibr">85</xref>). Although this systematic review is focused on the Alpha variant, new variants were emerging with an increasingly transmissibility and different patterns each time (<xref rid="ref86" ref-type="bibr">86</xref>). Thus, would be important to replicate this type of studies for new variants to enhance SARS-CoV-2 epidemiologic surveillance.</p><p>There are several limitations to this study. First, we included studies whose outcome was only laboratory-confirmed SARS-CoV-2 infection through RT-PCR tests. This can potentially exclude a considerable volume of studies detected by another method. Thus, underestimating our results since severe cases, often associated with more risk factors, were not always laboratory confirmed. Additionally, in the early stages of the pandemic, RT-PCR tests mainly supported diagnosis. Thus, their scarcity meant that their use was directed toward healthcare professionals, residents and professionals in residential homes and symptomatic people. This is reported in some of the articles included, which may skew the results toward populations with higher risk. Although rapid antigen SARS-CoV-2 tests could reach more people, they were only available in late 2020 (<xref rid="ref87" ref-type="bibr">87</xref>) or early 2021 (<xref rid="ref88" ref-type="bibr">88</xref>), influencing the case definition between countries. RT-PCR tests remained the gold standard method of diagnosis during the study period, providing more consistent and reliable results. Additionally, restricting the systematic review only to high-income countries could also left out countries with high incidence and potentially with important information to the study of this disease. Another limitation is the rapid evolution of the SARS-CoV-2 virus, which results in the appearance of variants that differ in transmissibility, meaning that as new variants appear, risk factors may also change. Comorbidities can also pose another limitation because, in some studies, they were self-reported and it was unclear whether it was an acute or chronic illness. For this meta-analysis, we extracted the ORs of the most complete analyses, whose variables adjusted had some variation between studies. Values adjusted for the higher number of confounders tend to be closer to the real effect. Still, they can also increase heterogeneity between studies, which results should be interpreted with caution. The contradictory evidence found, namely for cancer and cardiovascular diseases, possibly due to inconsistent terminology describing the diseases and methodology used to extract data, highlights the challenging task of comprehending the true effect of the underlying risk factors for SARS-CoV-2 infection. Results for diabetes should be interpreted cautiously since articles for meta-analysis were included regarding the type of diabetes (I and II). We performed a sensitivity analysis with the articles analyzing the same type of diabetes (type II), which were only two articles. Another limitation could be related to vaccination against COVID-19 since vaccines started to be administrated in late 2020, during our study period. However, vaccine effectiveness against SARS-CoV-2 infection is lower than against severe COVID-19 (<xref rid="ref89" ref-type="bibr">89</xref>). One study found that vaccine effectiveness against SARS-CoV-2 infection was lower among individuals with comorbidities than individuals without. Thus, it remains crucial to understand who is at higher risk for infection (<xref rid="ref90" ref-type="bibr">90</xref>).</p><p>This review has several strengths since it is, to our knowledge, the first SR and comprehensive meta-analysis of risk factors for SARS-CoV-2 infection in high-income countries, thus adding important knowledge to the SARS-CoV-2 infection. The meta-analyses were conducted using methods that were most suited for the data extracted, considering the heterogeneity of the studies included. Choosing only one measure of effect for the meta-analysis ensured the homogeneity between studies and thus yielded more robust results. The comprehensive search strategy and the databases included, returning a high number of studies, also strengthens this study. The reliability of the study selection criteria was confirmed by double screening of included articles and by testing a random sample (10%) of the extraction form. The study quality was also verified with quality assessment tools there are robust and widely used in literature.</p><p>In conclusion, our study demonstrated that men, people of black ethnicity, increased household number, and having diabetes diagnosis were associated with an increased risk for SARS-CoV-2 infection. However, cardiovascular diseases, asthma and ischemic heart disease were shown to be protective factors for this disease. One of the limitations of this meta-analysis relates to the heterogeneity between studies. Thus, future studies should consider how variables are measured to improve comparison between studies and enable a more robust gathering of information from academics.</p></sec><sec sec-type="data-availability" id="sec16"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="author-contributions" id="sec17"><title>Author contributions</title><p>MM: Conceptualization, Formal analysis, Investigation, Methodology, Software, Writing &#8211; original draft, Writing &#8211; review &amp; editing. SP: Data curation, Investigation, Validation, Writing &#8211; review &amp; editing. PS: Conceptualization, Formal analysis, Investigation, Methodology, Supervision, Validation, Writing &#8211; review &amp; editing. PA: Formal analysis, Methodology, Validation, Writing &#8211; review &amp; editing. HD: Data curation, Software, Writing &#8211; review &amp; editing. AL: Conceptualization, Formal analysis, Investigation, Methodology, Software, Supervision, Validation, Writing &#8211; review &amp; editing.</p></sec></body><back><sec sec-type="COI-statement" id="sec19"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="sec20"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec21"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fpubh.2024.1367480/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fpubh.2024.1367480/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Data_Sheet_1.ZIP" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll1">World Health Organization</collab></person-group>. WHO director-general&#8217;s opening remarks at the media briefing on COVID-19: 11 March 2020. Washington, D.C. (<year>2020</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020" ext-link-type="uri">https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll2">World Health Organization</collab></person-group>. WHO Coronavirus Disease (COVID-19) Dashboard. (<year>2021</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link><pub-id pub-id-type="pmid">37184163</pub-id></mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll3">United Nations</collab></person-group>. <source>UN response to COVID-19</source>. <publisher-loc>New York City</publisher-loc>: <publisher-name>United Nations</publisher-name> (<year>2021</year>).</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>L</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G</given-names></name></person-group>. <article-title>Risk factors for 2019 novel coronavirus disease (COVID-19) patients progressing to critical illness: a systematic review and meta-analysis</article-title>. <source>Aging</source>. (<year>2020</year>) <volume>12</volume>:<fpage>12410</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.18632/aging.103383</pub-id><pub-id pub-id-type="pmid">32575078</pub-id><pub-id pub-id-type="pmcid">PMC7343456</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Booth</surname><given-names>A</given-names></name><name name-style="western"><surname>Reed</surname><given-names>AB</given-names></name><name name-style="western"><surname>Ponzo</surname><given-names>S</given-names></name><name name-style="western"><surname>Yassaee</surname><given-names>A</given-names></name><name name-style="western"><surname>Aral</surname><given-names>M</given-names></name><name name-style="western"><surname>Plans</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis</article-title>. <source>medRxiv</source>. (<year>2020</year>) <volume>16</volume>:<fpage>e0247461</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0247461</pub-id><pub-id pub-id-type="pmcid">PMC7932512</pub-id><pub-id pub-id-type="pmid">33661992</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dzinamarira</surname><given-names>T</given-names></name><name name-style="western"><surname>Nkambule</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Hlongwa</surname><given-names>M</given-names></name><name name-style="western"><surname>Mhango</surname><given-names>M</given-names></name><name name-style="western"><surname>Iradukunda</surname><given-names>PG</given-names></name><name name-style="western"><surname>Chitungo</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Risk factors for COVID-19 infection among healthcare workers. A first report from a living systematic review and meta-analysis</article-title>. <source>Safety Health Work</source>. (<year>2022</year>) <volume>13</volume>:<fpage>263</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.shaw.2022.04.001</pub-id><pub-id pub-id-type="pmcid">PMC9004144</pub-id><pub-id pub-id-type="pmid">35433073</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gesesew</surname><given-names>HA</given-names></name><name name-style="western"><surname>DiN</surname><given-names>K</given-names></name><name name-style="western"><surname>Fetene</surname><given-names>DM</given-names></name><name name-style="western"><surname>Woldegiorgis</surname><given-names>M</given-names></name><name name-style="western"><surname>Kinfu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Geleto</surname><given-names>AB</given-names></name><etal/></person-group>. <article-title>Risk factors for COVID-19 infection, disease severity and related deaths in Africa: a systematic review</article-title>. <source>BMJ Open</source>. (<year>2021</year>) <volume>11</volume>:<fpage>e044618-10</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2020-044618</pub-id><pub-id pub-id-type="pmcid">PMC7896374</pub-id><pub-id pub-id-type="pmid">33602714</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bayati</surname><given-names>M</given-names></name></person-group>. <article-title>Why is COVID-19 more concentrated in countries with high economic status?</article-title><source>Iran J Public Health</source>. (<year>2021</year>) <volume>50</volume>:<fpage>1926</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.18502/ijph.v50i9.7081</pub-id><pub-id pub-id-type="pmid">34722396</pub-id><pub-id pub-id-type="pmcid">PMC8542832</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Lusignan</surname><given-names>S</given-names></name><name name-style="western"><surname>Dorward</surname><given-names>J</given-names></name><name name-style="western"><surname>Correa</surname><given-names>A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>N</given-names></name><name name-style="western"><surname>Akinyemi</surname><given-names>O</given-names></name><name name-style="western"><surname>Amirthalingam</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of general practitioners research and surveillance Centre primary care network: a cross-sectional study</article-title>. <source>Lancet Infect Dis</source>. (<year>2020</year>) <volume>20</volume>:<fpage>1034</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30371-6</pub-id><pub-id pub-id-type="pmid">32422204</pub-id><pub-id pub-id-type="pmcid">PMC7228715</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>FK</given-names></name><name name-style="western"><surname>Celis-Morales</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gray</surname><given-names>SR</given-names></name><name name-style="western"><surname>Katikireddi</surname><given-names>SV</given-names></name><name name-style="western"><surname>Niedzwiedz</surname><given-names>CL</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Modifiable and non-modifiable risk factors for COVID-19, and comparison to risk factors for influenza and pneumonia: results from a UK biobank prospective cohort study</article-title>. <source>BMJ Open</source>. (<year>2020</year>) <volume>10</volume>:<fpage>e040402</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2020-040402</pub-id>, PMID: <pub-id pub-id-type="pmid">33444201</pub-id><pub-id pub-id-type="pmcid">PMC7678347</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>DW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Chang</surname><given-names>JH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>YJ</given-names></name><etal/></person-group>. <article-title>Does diabetes increase the risk of contracting COVID-19? A population-based study in Korea</article-title>. <source>Diabetes Metab J</source>. (<year>2020</year>) <volume>44</volume>:<fpage>897</fpage>&#8211;<lpage>907</lpage>. doi: <pub-id pub-id-type="doi">10.4093/dmj.2020.0199</pub-id>, PMID: <pub-id pub-id-type="pmid">33389959</pub-id><pub-id pub-id-type="pmcid">PMC7801768</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pugliese</surname><given-names>G</given-names></name><name name-style="western"><surname>Vitale</surname><given-names>M</given-names></name><name name-style="western"><surname>Resi</surname><given-names>V</given-names></name><name name-style="western"><surname>Orsi</surname><given-names>E</given-names></name></person-group>. <article-title>Is diabetes mellitus a risk factor for COronaVIrus disease 19 (COVID-19)?</article-title><source>Acta Diabetol</source>. (<year>2020</year>) <volume>57</volume>:<fpage>1275</fpage>&#8211;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00592-020-01586-6</pub-id>, PMID: <pub-id pub-id-type="pmid">32865671</pub-id><pub-id pub-id-type="pmcid">PMC7456750</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roel</surname><given-names>E</given-names></name><name name-style="western"><surname>Pistillo</surname><given-names>A</given-names></name><name name-style="western"><surname>Recalde</surname><given-names>M</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Bertol&#237;n</surname><given-names>S</given-names></name><name name-style="western"><surname>Arag&#243;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Cancer and the risk of COVID-19 diagnosis, hospitalisation, and death: a population-based multi-state cohort study including 4,618,377 adults in Catalonia, Spain</article-title>. <source>Int J Cancer</source>. (<year>2022</year>) <volume>150</volume>:<fpage>782</fpage>&#8211;<lpage>94</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ijc.33846</pub-id><pub-id pub-id-type="pmid">34655476</pub-id><pub-id pub-id-type="pmcid">PMC8652827</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangone</surname><given-names>L</given-names></name><name name-style="western"><surname>Gioia</surname><given-names>F</given-names></name><name name-style="western"><surname>Mancuso</surname><given-names>P</given-names></name><name name-style="western"><surname>Bisceglia</surname><given-names>I</given-names></name><name name-style="western"><surname>Ottone</surname><given-names>M</given-names></name><name name-style="western"><surname>Vicentini</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Cumulative COVID-19 incidence, mortality, and prognosis in cancer survivors: a population-based study in Reggio Emilia, northern Italy</article-title>. <source>medRxiv</source>. (<year>2021</year>) <volume>149</volume>:<fpage>820</fpage>&#8211;<lpage>826</lpage>. doi: <pub-id pub-id-type="doi">10.1002/ijc.33601</pub-id><pub-id pub-id-type="pmcid">PMC8250826</pub-id><pub-id pub-id-type="pmid">33861870</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Earnest</surname><given-names>R</given-names></name><name name-style="western"><surname>Uddin</surname><given-names>R</given-names></name><name name-style="western"><surname>Matluk</surname><given-names>N</given-names></name><name name-style="western"><surname>Renzette</surname><given-names>N</given-names></name><name name-style="western"><surname>Turbett</surname><given-names>SE</given-names></name><name name-style="western"><surname>Siddle</surname><given-names>KJ</given-names></name><etal/></person-group>. <article-title>Comparative transmissibility of SARS-CoV-2 variants Delta and alpha in New England, USA</article-title>. <source>Cell Rep Med</source>. (<year>2022</year>) <volume>3</volume>:<fpage>100583</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.xcrm.2022.100583</pub-id>, PMID: <pub-id pub-id-type="pmid">35480627</pub-id><pub-id pub-id-type="pmcid">PMC8913280</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Varea-Jim&#233;nez</surname><given-names>E</given-names></name><name name-style="western"><surname>Aznar Cano</surname><given-names>E</given-names></name><name name-style="western"><surname>Vega-Piris</surname><given-names>L</given-names></name><name name-style="western"><surname>Mart&#237;nez S&#225;nchez</surname><given-names>EV</given-names></name><name name-style="western"><surname>Mazagatos</surname><given-names>C</given-names></name><name name-style="western"><surname>Garc&#237;a San Miguel Rodr&#237;guez Alarc&#243;n</surname><given-names>L</given-names></name><etal/></person-group>. Comparative severity of COVID-19 cases caused by alpha, delta or omicron SARS-CoV-2 variants and its association with vaccination. Enferm Infecc Microbiol Clin. (<year>2022</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0213005X22002816" ext-link-type="uri">https://linkinghub.elsevier.com/retrieve/pii/S0213005X22002816</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eimce.2022.11.021</pub-id><pub-id pub-id-type="pmcid">PMC9890374</pub-id><pub-id pub-id-type="pmid">36737369</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trobajo-Sanmart&#237;n</surname><given-names>C</given-names></name><name name-style="western"><surname>Mart&#237;nez-Baz</surname><given-names>I</given-names></name><name name-style="western"><surname>Miqueleiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Huerta</surname><given-names>M</given-names></name><name name-style="western"><surname>Burgui</surname><given-names>C</given-names></name><name name-style="western"><surname>Casado</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Differences in transmission between SARS-CoV-2 alpha (B.1.1.7) and Delta (B.1.617.2) variants</article-title>. <source>Microbiol Spectr</source>. (<year>2022</year>) <volume>10</volume>:<fpage>1</fpage>&#8211;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1128/spectrum.00008-22</pub-id><pub-id pub-id-type="pmcid">PMC9045255</pub-id><pub-id pub-id-type="pmid">35412379</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Hodcrof</surname><given-names>EB</given-names></name></person-group>. Covariants: SARS-CoV-2 mutations and variants of interest. (<year>2021</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://covariants.org/per-country" ext-link-type="uri">https://covariants.org/per-country</ext-link></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<fpage>n71</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stroup</surname><given-names>DF</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>JA</given-names></name><name name-style="western"><surname>Morton</surname><given-names>SC</given-names></name><name name-style="western"><surname>Olkin</surname><given-names>I</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>GD</given-names></name><name name-style="western"><surname>Rennie</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group</article-title>. <source>JAMA</source>. (<year>2000</year>) <volume>283</volume>:<fpage>2008</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.283.15.2008</pub-id><pub-id pub-id-type="pmid">10789670</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll4">World Bank</collab></person-group>. High income: data. (<year>2021</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.worldbank.org/income-level/high-income?view=chart" ext-link-type="uri">https://data.worldbank.org/income-level/high-income?view=chart</ext-link></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Ouzzani</surname><given-names>M</given-names></name><name name-style="western"><surname>Hammady</surname><given-names>H</given-names></name><name name-style="western"><surname>Fedorowicz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Elmagarmid</surname><given-names>A</given-names></name></person-group>. Rayyan &#8211; intelligent systematic review. (<year>2022</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.rayyan.ai/" ext-link-type="uri">https://www.rayyan.ai/</ext-link><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13643-016-0384-4</pub-id><pub-id pub-id-type="pmcid">PMC5139140</pub-id><pub-id pub-id-type="pmid">27919275</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moola</surname><given-names>S</given-names></name><name name-style="western"><surname>Munn</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tufanaru</surname><given-names>C</given-names></name><name name-style="western"><surname>Aromataris</surname><given-names>E</given-names></name><name name-style="western"><surname>Sears</surname><given-names>K</given-names></name><name name-style="western"><surname>Sfetcu</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Joanna Briggs Institute. Checklist for qualitative research: analytical cross sectional studies</article-title>. Adelaide: Joanna Briggs Institute. (<year>2017</year>). <fpage>6</fpage> p. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jbi.global/critical-appraisal-tools" ext-link-type="uri">https://jbi.global/critical-appraisal-tools</ext-link> (Accessed January 13, 2020).</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Wells</surname><given-names>G</given-names></name><name name-style="western"><surname>Shea</surname><given-names>B</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>D</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>J</given-names></name><name name-style="western"><surname>Welch</surname><given-names>V</given-names></name><name name-style="western"><surname>Losos</surname><given-names>M</given-names></name><etal/></person-group>. Ottawa Health Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp" ext-link-type="uri">https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>MM</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>U</given-names></name><name name-style="western"><surname>Walther</surname><given-names>B</given-names></name><name name-style="western"><surname>Atique</surname><given-names>S</given-names></name><name name-style="western"><surname>Dubey</surname><given-names>NK</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>PA</given-names></name><etal/></person-group>. <article-title>Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis</article-title>. <source>Neuroepidemiology</source>. (<year>2017</year>) <volume>47</volume>:<fpage>181</fpage>&#8211;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000454881</pub-id><pub-id pub-id-type="pmid">28013304</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>R</given-names></name></person-group>. <article-title>Cochrane consumers and communication review group reviews: meta-analysis</article-title>. <source>Cochrane Cons Commun Rev Group</source>. (<year>2016</year>) <volume>2016</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. doi: <pub-id pub-id-type="doi">10.1002/14651858.CD010825.pub2</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michelen</surname><given-names>M</given-names></name><name name-style="western"><surname>Manoharan</surname><given-names>L</given-names></name><name name-style="western"><surname>Elkheir</surname><given-names>N</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V</given-names></name><name name-style="western"><surname>Dagens</surname><given-names>A</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Characterising long COVID: a living systematic review</article-title>. <source>BMJ Glob Health</source>. (<year>2021</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjgh-2021-005427</pub-id><pub-id pub-id-type="pmcid">PMC8478580</pub-id><pub-id pub-id-type="pmid">34580069</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>B</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name></person-group>. <article-title>A meta-analysis of risk factors for depression in adults and children after natural disasters</article-title>. <source>BMC Public Health</source>. (<year>2014</year>) <volume>14</volume>:<fpage>623</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1471-2458-14-623</pub-id><pub-id pub-id-type="pmid">24941890</pub-id><pub-id pub-id-type="pmcid">PMC4077641</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deeks</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group>. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane (2022). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.training.cochrane.org/handbook" ext-link-type="uri">https://www.training.cochrane.org/handbook</ext-link> (Accessed August 26, 2022).</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Borenstein</surname><given-names>M</given-names></name><name name-style="western"><surname>Hedges</surname><given-names>LV</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name><name name-style="western"><surname>Rothstein</surname><given-names>HR</given-names></name></person-group>. <article-title>Introduction to meta-analysis. Chapter 13: Fixed-Effect Versus Random-Effects Models</article-title> (Pages: <fpage>77</fpage>&#8211;<lpage>86</lpage>).</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll5">IBM Corp</collab></person-group>. <source>IBM SPSS statistics for Macintosh, version 28.0.1.0</source>. <publisher-loc>Armonk, NY</publisher-loc>: IBM Corp. (<year>2021</year>).</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Didikoglu</surname><given-names>A</given-names></name><name name-style="western"><surname>Maharani</surname><given-names>A</given-names></name><name name-style="western"><surname>Pendleton</surname><given-names>N</given-names></name><name name-style="western"><surname>Canal</surname><given-names>MM</given-names></name><name name-style="western"><surname>Payton</surname><given-names>A</given-names></name></person-group>. <article-title>Early life factors and COVID-19 infection in England: a prospective analysis of UK biobank participants</article-title>. <source>Early Hum Dev</source>. (<year>2021</year>) <volume>155</volume>:<fpage>105326</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.earlhumdev.2021.105326</pub-id>, PMID: <pub-id pub-id-type="pmid">33578220</pub-id><pub-id pub-id-type="pmcid">PMC7860946</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vila-C&#243;rcoles</surname><given-names>A</given-names></name><name name-style="western"><surname>Ochoa-Gondar</surname><given-names>O</given-names></name><name name-style="western"><surname>Satu&#233;-Gracia</surname><given-names>EM</given-names></name><name name-style="western"><surname>Torrente-Fraga</surname><given-names>C</given-names></name><name name-style="western"><surname>Gomez-Bertomeu</surname><given-names>F</given-names></name><name name-style="western"><surname>Vila-Rovira</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain</article-title>. <source>BMJ Open</source>. (<year>2020</year>) <volume>10</volume>:<fpage>e041577-13</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2020-041577</pub-id><pub-id pub-id-type="pmcid">PMC7733229</pub-id><pub-id pub-id-type="pmid">33303459</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niedzwiedz</surname><given-names>CL</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>CA</given-names></name><name name-style="western"><surname>Jani</surname><given-names>BD</given-names></name><name name-style="western"><surname>Demou</surname><given-names>E</given-names></name><name name-style="western"><surname>Ho</surname><given-names>FK</given-names></name><name name-style="western"><surname>Celis-Morales</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK biobank</article-title>. <source>BMC Med</source>. (<year>2020</year>) <volume>18</volume>:<fpage>160</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-020-01640-8</pub-id>, PMID: <pub-id pub-id-type="pmid">32466757</pub-id><pub-id pub-id-type="pmcid">PMC7255908</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>HR</given-names></name><name name-style="western"><surname>Adhikari</surname><given-names>S</given-names></name><name name-style="western"><surname>Pulgarin</surname><given-names>C</given-names></name><name name-style="western"><surname>Troxel</surname><given-names>AB</given-names></name><name name-style="western"><surname>Iturrate</surname><given-names>E</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>SB</given-names></name><etal/></person-group>. <article-title>Renin&#8211;angiotensin&#8211;aldosterone system inhibitors and risk of COVID-19</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>2441</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2008975</pub-id>, PMID: <pub-id pub-id-type="pmid">32356628</pub-id><pub-id pub-id-type="pmcid">PMC7206932</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pablos</surname><given-names>JL</given-names></name><name name-style="western"><surname>Abasolo</surname><given-names>L</given-names></name><name name-style="western"><surname>Alvaro-Gracia</surname><given-names>JM</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>R</given-names></name><name name-style="western"><surname>Castrejon</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases</article-title>. <source>Ann Rheum Dis</source>. (<year>2020</year>) <volume>79</volume>:<fpage>1170</fpage>&#8211;<lpage>3</lpage>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217763</pub-id>, PMID: <pub-id pub-id-type="pmid">32532753</pub-id><pub-id pub-id-type="pmcid">PMC7299645</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>R</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>CT</given-names></name><name name-style="western"><surname>Morton</surname><given-names>CE</given-names></name><name name-style="western"><surname>Hulme</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Schultze</surname><given-names>A</given-names></name><name name-style="western"><surname>MacKenna</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>397</volume>:<fpage>1711</fpage>&#8211;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00634-6</pub-id>, PMID: <pub-id pub-id-type="pmid">33939953</pub-id><pub-id pub-id-type="pmcid">PMC8087292</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Barish</surname><given-names>PN</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>PA</given-names></name><name name-style="western"><surname>Kistler</surname><given-names>A</given-names></name><name name-style="western"><surname>Neff</surname><given-names>N</given-names></name><name name-style="western"><surname>Kamm</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Clinical features, diagnostics, and outcomes of patients presenting with acute respiratory illness: a retrospective cohort study of patients with and without COVID-19</article-title>. <source>EClinicalMedicine</source>. (<year>2020</year>) <volume>27</volume>:<fpage>100518</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100518</pub-id><pub-id pub-id-type="pmid">32864588</pub-id><pub-id pub-id-type="pmcid">PMC7447618</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cromer</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Lakhani</surname><given-names>CM</given-names></name><name name-style="western"><surname>Wexler</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Burnett-Bowie</surname><given-names>SAM</given-names></name><name name-style="western"><surname>Udler</surname><given-names>M</given-names></name><name name-style="western"><surname>Patel</surname><given-names>CJ</given-names></name></person-group>. <article-title>Geospatial analysis of individual and community-level socioeconomic factors impacting SARS-CoV-2 prevalence and outcomes</article-title>. <source>medRxiv</source>. (<year>2020</year>). doi: <pub-id pub-id-type="doi">10.1101/2020.09.30.20201830</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SW</given-names></name><name name-style="western"><surname>Yang</surname><given-names>JM</given-names></name><name name-style="western"><surname>Moon</surname><given-names>SY</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>IK</given-names></name><name name-style="western"><surname>Ha</surname><given-names>EK</given-names></name><name name-style="western"><surname>Kim</surname><given-names>SY</given-names></name><etal/></person-group>. <article-title>Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study</article-title>. <source>Lancet Psychiatry</source>. (<year>2020</year>) <volume>7</volume>:<fpage>1025</fpage>&#8211;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2215-0366(20)30421-1</pub-id><pub-id pub-id-type="pmid">32950066</pub-id><pub-id pub-id-type="pmcid">PMC7498216</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Miyata</surname><given-names>T</given-names></name><name name-style="western"><surname>Dasarathy</surname><given-names>S</given-names></name><name name-style="western"><surname>Rotroff</surname><given-names>DM</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Effect of acid suppressants on the risk of COVID-19: a propensity score-matched study using UK biobank</article-title>. <source>Gastroenterology</source>. (<year>2021</year>) <volume>160</volume>:<fpage>455</fpage>&#8211;<lpage>458.e5</lpage>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2020.09.028</pub-id><pub-id pub-id-type="pmid">32980342</pub-id><pub-id pub-id-type="pmcid">PMC7513758</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>YZ</given-names></name><name name-style="western"><surname>Travaglio</surname><given-names>M</given-names></name><name name-style="western"><surname>Popovic</surname><given-names>R</given-names></name><name name-style="western"><surname>Leal</surname><given-names>NS</given-names></name><name name-style="western"><surname>Martins</surname><given-names>LM</given-names></name></person-group>. <article-title>Alzheimer&#8217;s and Parkinson&#8217;s diseases predict different COVID-19 outcomes: a UK biobank study</article-title>. <source>Geriatrics</source>. (<year>2021</year>) <volume>6</volume>:<fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.3390/geriatrics6010010</pub-id><pub-id pub-id-type="pmid">33530357</pub-id><pub-id pub-id-type="pmcid">PMC7839041</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raisi-Estabragh</surname><given-names>Z</given-names></name><name name-style="western"><surname>McCracken</surname><given-names>C</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>J</given-names></name><name name-style="western"><surname>Fung</surname><given-names>K</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>JM</given-names></name><name name-style="western"><surname>Khanji</surname><given-names>MY</given-names></name><etal/></person-group>. <article-title>Adverse cardiovascular magnetic resonance phenotypes are associated with greater likelihood of incident coronavirus disease 2019: findings from the UK biobank</article-title>. <source>Aging Clin Exp Res</source>. (<year>2021</year>) <volume>33</volume>:<fpage>1133</fpage>&#8211;<lpage>44</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40520-021-01808-z</pub-id>, PMID: <pub-id pub-id-type="pmid">33683678</pub-id><pub-id pub-id-type="pmcid">PMC7938275</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Israel</surname><given-names>A</given-names></name><name name-style="western"><surname>Feldhamer</surname><given-names>I</given-names></name><name name-style="western"><surname>Lahad</surname><given-names>A</given-names></name><name name-style="western"><surname>Levin-Zamir</surname><given-names>D</given-names></name><name name-style="western"><surname>Lavie</surname><given-names>G</given-names></name></person-group>. <article-title>Smoking and the risk of COVID-19 in a large observational population study</article-title>. <source>medRxiv</source>. doi: <pub-id pub-id-type="doi">10.1101/2020.06.01.20118877</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Bangaru</surname><given-names>S</given-names></name><name name-style="western"><surname>Arneson</surname><given-names>D</given-names></name><name name-style="western"><surname>Dasharathy</surname><given-names>S</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Case&#8211;control study of the association of chronic acid suppression and social determinants of health with COVID-19 infection</article-title>. <source>Sci Rep</source>. (<year>2021</year>) <volume>11</volume>:<fpage>20987</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-00367-7</pub-id>, PMID: <pub-id pub-id-type="pmid">34697319</pub-id><pub-id pub-id-type="pmcid">PMC8545937</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kjetland</surname><given-names>EF</given-names></name><name name-style="western"><surname>Kalleberg</surname><given-names>KT</given-names></name><name name-style="western"><surname>S&#248;raas</surname><given-names>CL</given-names></name><name name-style="western"><surname>Hammarstr&#246;m</surname><given-names>B</given-names></name><name name-style="western"><surname>Myklebust</surname><given-names>&#197;</given-names></name><name name-style="western"><surname>Jenum</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Risk factors for community transmission of SARS-CoV-2: a cross-sectional study in 116,678 people</article-title>. <source>medRxiv</source>. (<year>2020</year>). doi: <pub-id pub-id-type="doi">10.1101/2020.12.23.20248514v1</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mancia</surname><given-names>G</given-names></name><name name-style="western"><surname>Rea</surname><given-names>F</given-names></name><name name-style="western"><surname>Ludergnani</surname><given-names>M</given-names></name><name name-style="western"><surname>Apolone</surname><given-names>G</given-names></name><name name-style="western"><surname>Corrao</surname><given-names>G</given-names></name></person-group>. <article-title>Renin&#8211;angiotensin&#8211;aldosterone system blockers and the risk of COVID-19</article-title>. <source>New England J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>2431</fpage>&#8211;<lpage>40</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa2006923</pub-id>, PMID: <pub-id pub-id-type="pmid">32356627</pub-id><pub-id pub-id-type="pmcid">PMC7206933</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>J</given-names></name><name name-style="western"><surname>Son</surname><given-names>M</given-names></name></person-group>. <article-title>Update on association between exposure to renin-angiotensin-aldosterone system inhibitors and coronavirus disease 2019 in South Korea</article-title>. <source>Korean J Intern Med</source>. (<year>2021</year>) <volume>36</volume>:<fpage>S114</fpage>&#8211;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.3904/kjim.2020.380</pub-id>, PMID: <pub-id pub-id-type="pmid">32872736</pub-id><pub-id pub-id-type="pmcid">PMC8009148</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>KHH</given-names></name><name name-style="western"><surname>Hornsby</surname><given-names>WE</given-names></name><name name-style="western"><surname>Klunder</surname><given-names>B</given-names></name><name name-style="western"><surname>Krause</surname><given-names>A</given-names></name><name name-style="western"><surname>Driscoll</surname><given-names>A</given-names></name><name name-style="western"><surname>Kulka</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Exposure and risk factors for COVID-19 and the impact of staying home on Michigan residents</article-title>. <source>PLoS One</source>. (<year>2021</year>) <volume>16</volume>:<fpage>e0246447</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0246447</pub-id><pub-id pub-id-type="pmid">33556117</pub-id><pub-id pub-id-type="pmcid">PMC7870003</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chadeau-Hyam</surname><given-names>M</given-names></name><name name-style="western"><surname>Bodinier</surname><given-names>B</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>J</given-names></name><name name-style="western"><surname>Whitaker</surname><given-names>MD</given-names></name><name name-style="western"><surname>Tzoulaki</surname><given-names>I</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data</article-title>. <source>Int J Epidemiol</source>. (<year>2020</year>) <volume>49</volume>:<fpage>1454</fpage>&#8211;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ije/dyaa134</pub-id>, PMID: <pub-id pub-id-type="pmid">32814959</pub-id><pub-id pub-id-type="pmcid">PMC7454561</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ji</surname><given-names>W</given-names></name><name name-style="western"><surname>Huh</surname><given-names>K</given-names></name><name name-style="western"><surname>Kang</surname><given-names>M</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J</given-names></name><name name-style="western"><surname>Bae</surname><given-names>GH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Effect of underlying comorbidities on the infection and severity of COVID-19 in Korea: a Nationwide case-control study</article-title>. <source>J Korean Med Sci</source>. (<year>2020</year>) <volume>35</volume>:<fpage>e237</fpage>. doi: <pub-id pub-id-type="doi">10.3346/jkms.2020.35.e237</pub-id>, PMID: <pub-id pub-id-type="pmid">32597048</pub-id><pub-id pub-id-type="pmcid">PMC7324262</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>SC</given-names></name><name name-style="western"><surname>Won</surname><given-names>SY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>NH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>H</given-names></name><name name-style="western"><surname>Youk</surname><given-names>TM</given-names></name><name name-style="western"><surname>Lee</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections: a nationwide population-based study</article-title>. <source>Ann Transl Med</source>. (<year>2021</year>) <volume>9</volume>:<fpage>211</fpage>. doi: <pub-id pub-id-type="doi">10.21037/atm-20-5958</pub-id><pub-id pub-id-type="pmid">33708838</pub-id><pub-id pub-id-type="pmcid">PMC7940880</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egede</surname><given-names>LE</given-names></name><name name-style="western"><surname>Walker</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Garacci</surname><given-names>E</given-names></name><name name-style="western"><surname>Raymond</surname><given-names>JR</given-names></name></person-group>. <article-title>Racial/ethnic differences in COVID-19 screening, hospitalization, and mortality in Southeast Wisconsin</article-title>. <source>Health Aff</source>. (<year>2020</year>) <volume>39</volume>:<fpage>1926</fpage>&#8211;<lpage>34</lpage>. doi: <pub-id pub-id-type="doi">10.1377/hlthaff.2020.01081</pub-id>, PMID: <pub-id pub-id-type="pmid">33136498</pub-id><pub-id pub-id-type="pmcid">PMC7768944</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz-Price</surname><given-names>LS</given-names></name><name name-style="western"><surname>Nattinger</surname><given-names>AB</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>F</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>R</given-names></name><name name-style="western"><surname>Gmehlin</surname><given-names>CG</given-names></name><name name-style="western"><surname>Perez</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Racial disparities in incidence and outcomes among patients with COVID-19</article-title>. <source>JAMA Netw Open</source>. (<year>2020</year>) <volume>3</volume>:<fpage>e2021892</fpage>. doi: <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.21892</pub-id>, PMID: <pub-id pub-id-type="pmid">32975575</pub-id><pub-id pub-id-type="pmcid">PMC7519420</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vahidy</surname><given-names>FS</given-names></name><name name-style="western"><surname>Pan</surname><given-names>AP</given-names></name><name name-style="western"><surname>Ahnstedt</surname><given-names>H</given-names></name><name name-style="western"><surname>Munshi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Choi</surname><given-names>HA</given-names></name><name name-style="western"><surname>Tiruneh</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area</article-title>. <source>PLoS One</source>. (<year>2021</year>) <volume>16</volume>:<fpage>e0245556</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0245556</pub-id>, PMID: <pub-id pub-id-type="pmid">33439908</pub-id><pub-id pub-id-type="pmcid">PMC7806140</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vahidy</surname><given-names>FS</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>JC</given-names></name><name name-style="western"><surname>Meeks</surname><given-names>JR</given-names></name><name name-style="western"><surname>Khan</surname><given-names>O</given-names></name><name name-style="western"><surname>Pan</surname><given-names>A</given-names></name><name name-style="western"><surname>Jones</surname><given-names>SL</given-names></name><etal/></person-group>. <article-title>Racial and ethnic disparities in SARS-CoV-2 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population</article-title>. <source>BMJ Open</source>. (<year>2020</year>) <volume>10</volume>:<fpage>e039849</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2020-039849</pub-id>, PMID: <pub-id pub-id-type="pmid">32784264</pub-id><pub-id pub-id-type="pmcid">PMC7418666</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamed</surname><given-names>E</given-names></name><name name-style="western"><surname>Syed</surname><given-names>MA</given-names></name><name name-style="western"><surname>Alnuaimi</surname><given-names>AS</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>M</given-names></name><name name-style="western"><surname>Alemrayat</surname><given-names>B</given-names></name><name name-style="western"><surname>Muktar</surname><given-names>AAM</given-names></name><etal/></person-group>. <article-title>Haematological abnormalities and risk of COVID-19 infection in adult patients attending primary healthcare settings</article-title>. <source>Hematol Rep</source>. (<year>2020</year>) <volume>12</volume>:<fpage>8829</fpage>. doi: <pub-id pub-id-type="doi">10.4081/hr.2020.8829</pub-id>, PMID: <pub-id pub-id-type="pmid">33282166</pub-id><pub-id pub-id-type="pmcid">PMC7686855</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Son</surname><given-names>M</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S</given-names></name></person-group>. <article-title>Association between renin-angiotensin-aldosterone system inhibitors and COVID-19 infection in South Korea</article-title>. <source>Hypertension</source>. (<year>2020</year>) <volume>76</volume>:<fpage>742</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.120.15464</pub-id>, PMID: <pub-id pub-id-type="pmid">32654557</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Chaimani</surname><given-names>A</given-names></name></person-group>. <article-title>Challenges in meta-analyses with observational studies</article-title>. <source>Evid Based Ment Health</source>. (<year>2020</year>) <volume>23</volume>:<fpage>83</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1136/ebmental-2019-300129</pub-id>, PMID: <pub-id pub-id-type="pmid">32139442</pub-id><pub-id pub-id-type="pmcid">PMC10231593</pub-id></mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abate</surname><given-names>BB</given-names></name><name name-style="western"><surname>Kassie</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kassaw</surname><given-names>MW</given-names></name><name name-style="western"><surname>Aragie</surname><given-names>TG</given-names></name><name name-style="western"><surname>Masresha</surname><given-names>SA</given-names></name></person-group>. <article-title>Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis</article-title>. <source>BMJ Open</source>. (<year>2020</year>) <volume>10</volume>:<fpage>e040129</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2020-040129</pub-id><pub-id pub-id-type="pmcid">PMC7539579</pub-id><pub-id pub-id-type="pmid">33028563</pub-id></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pijls</surname><given-names>BG</given-names></name><name name-style="western"><surname>Jolani</surname><given-names>S</given-names></name><name name-style="western"><surname>Atherley</surname><given-names>A</given-names></name><name name-style="western"><surname>Derckx</surname><given-names>RT</given-names></name><name name-style="western"><surname>Dijkstra</surname><given-names>JIR</given-names></name><name name-style="western"><surname>Franssen</surname><given-names>GHL</given-names></name><etal/></person-group>. <article-title>Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies</article-title>. <source>BMJ Open</source>. (<year>2021</year>) <volume>11</volume>:<fpage>e044640</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjopen-2020-044640</pub-id>, PMID: <pub-id pub-id-type="pmid">33431495</pub-id><pub-id pub-id-type="pmcid">PMC7802392</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll6">World Health Organization</collab></person-group>. <source>Sex, gender and influenza</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wambier</surname><given-names>CG</given-names></name><name name-style="western"><surname>Goren</surname><given-names>A</given-names></name></person-group>. <article-title>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated</article-title>. <source>J Am Acad Dermatol</source>. (<year>2020</year>) <volume>83</volume>:<fpage>308</fpage>&#8211;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2020.04.032</pub-id>, PMID: <pub-id pub-id-type="pmid">32283245</pub-id><pub-id pub-id-type="pmcid">PMC7151476</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><collab id="coll7">Public Health England</collab></person-group>. <source>Disparities in the risk and outcomes of COVID-19</source>. London, GOV UK: <publisher-name>PHE Publications</publisher-name> (<year>2020</year>). <fpage>89</fpage> p.</mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ellingson</surname><given-names>MK</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P</given-names></name><name name-style="western"><surname>Israelow</surname><given-names>B</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>C</given-names></name><name name-style="western"><surname>Klein</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Sex differences in immune responses that underlie COVID-19 disease outcomes</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>588</volume>:<fpage>315</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41586-020-2700-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32846427</pub-id><pub-id pub-id-type="pmcid">PMC7725931</pub-id></mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sompa</surname><given-names>AW</given-names></name><name name-style="western"><surname>Harun</surname><given-names>H</given-names></name><name name-style="western"><surname>Mimika</surname><given-names>RA</given-names></name><name name-style="western"><surname>Riksanto</surname><given-names>R</given-names></name></person-group>. <article-title>Neurological manifestations of COVID-19 in Indonesia: assessment of the role of sex and age</article-title>. <source>Narra J</source>. (<year>2023</year>) <volume>3</volume>:<fpage>e277</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.52225/narra.v3i3.277</pub-id>, PMID: <pub-id pub-id-type="pmid">38450343</pub-id><pub-id pub-id-type="pmcid">PMC10916454</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll8">Global Health 50/50</collab></person-group>. The sex, gender and COVID-19 project. (<year>2022</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://globalhealth5050.org/covid19" ext-link-type="uri">https://globalhealth5050.org/covid19</ext-link></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agyemang</surname><given-names>C</given-names></name><name name-style="western"><surname>Richters</surname><given-names>A</given-names></name><name name-style="western"><surname>Jolani</surname><given-names>S</given-names></name><name name-style="western"><surname>Hendriks</surname><given-names>S</given-names></name><name name-style="western"><surname>Zalpuri</surname><given-names>S</given-names></name><name name-style="western"><surname>Yu</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Ethnic minority status as social determinant for COVID-19 infection, hospitalisation, severity, ICU admission and deaths in the early phase of the pandemic: a meta-analysis</article-title>. <source>BMJ Glob Health</source>. (<year>2021</year>) <volume>6</volume>:<fpage>7433</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmjgh-2021-007433</pub-id><pub-id pub-id-type="pmcid">PMC8573300</pub-id><pub-id pub-id-type="pmid">34740916</pub-id></mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raharja</surname><given-names>A</given-names></name><name name-style="western"><surname>Tamara</surname><given-names>A</given-names></name><name name-style="western"><surname>Kok</surname><given-names>LT</given-names></name></person-group>. <article-title>Association between ethnicity and severe COVID-19 disease: a systematic review and meta-analysis</article-title>. <source>J Racial Ethn Health Disparities</source>. (<year>2021</year>) <volume>8</volume>:<fpage>1563</fpage>&#8211;<lpage>72</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40615-020-00921-5</pub-id>, PMID: <pub-id pub-id-type="pmid">33180278</pub-id><pub-id pub-id-type="pmcid">PMC7659894</pub-id></mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>McAuliffe</surname><given-names>M</given-names></name></person-group>. <source>AT. World migration report 2022</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>International Organization of Migration (IOM)</publisher-name> (<year>2021</year>).</mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gou</surname><given-names>X</given-names></name><name name-style="western"><surname>Pu</surname><given-names>K</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis</article-title>. <source>Int J Infect Dis</source>. (<year>2020</year>) <volume>94</volume>:<fpage>91</fpage>&#8211;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.017</pub-id>, PMID: <pub-id pub-id-type="pmid">32173574</pub-id><pub-id pub-id-type="pmcid">PMC7194638</pub-id></mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharifi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Payab</surname><given-names>M</given-names></name><name name-style="western"><surname>Mohammadi-Vajari</surname><given-names>E</given-names></name><name name-style="western"><surname>Aghili</surname><given-names>SMM</given-names></name><name name-style="western"><surname>Sharifi</surname><given-names>F</given-names></name><name name-style="western"><surname>Mehrdad</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review</article-title> (<year>2021</year>) <volume>20</volume>:<fpage>1743</fpage>&#8211;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40200-021-00822-2</pub-id>,<pub-id pub-id-type="pmcid">PMC8233632</pub-id><pub-id pub-id-type="pmid">34222055</pub-id></mixed-citation></ref><ref id="ref73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>PT</given-names></name><name name-style="western"><surname>Ali</surname><given-names>Z</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>AE</given-names></name><name name-style="western"><surname>Bonell</surname><given-names>A</given-names></name><name name-style="western"><surname>Cerami</surname><given-names>C</given-names></name><name name-style="western"><surname>Drakesmith</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>The role of nutrition in COVID-19 susceptibility and severity of disease: a systematic review</article-title>. <source>J Nutr</source>. (<year>2021</year>) <volume>151</volume>:<fpage>1854</fpage>&#8211;<lpage>78</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jn/nxab059</pub-id>, PMID: <pub-id pub-id-type="pmid">33982105</pub-id><pub-id pub-id-type="pmcid">PMC8194602</pub-id></mixed-citation></ref><ref id="ref74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morais-Almeida</surname><given-names>M</given-names></name><name name-style="western"><surname>Pit&#233;</surname><given-names>H</given-names></name><name name-style="western"><surname>Aguiar</surname><given-names>R</given-names></name><name name-style="western"><surname>Ansotegui</surname><given-names>I</given-names></name><name name-style="western"><surname>Bousquet</surname><given-names>J</given-names></name></person-group>. <article-title>Asthma and the coronavirus disease 2019 pandemic: a literature review</article-title>. <source>Int Arch Allergy Immunol</source>. (<year>2020</year>) <volume>181</volume>:<fpage>680</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1159/000509057</pub-id>, PMID: <pub-id pub-id-type="pmid">32516795</pub-id><pub-id pub-id-type="pmcid">PMC7316650</pub-id></mixed-citation></ref><ref id="ref75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halpin</surname><given-names>DMG</given-names></name><name name-style="western"><surname>Faner</surname><given-names>R</given-names></name><name name-style="western"><surname>Sibila</surname><given-names>O</given-names></name><name name-style="western"><surname>Badia</surname><given-names>JR</given-names></name><name name-style="western"><surname>Agusti</surname><given-names>A</given-names></name></person-group>. <article-title>Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?</article-title><source>Lancet Respir Med</source>. (<year>2020</year>) <volume>8</volume>:<fpage>436</fpage>&#8211;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30167-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32251625</pub-id><pub-id pub-id-type="pmcid">PMC7270536</pub-id></mixed-citation></ref><ref id="ref76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Kawase</surname><given-names>M</given-names></name><name name-style="western"><surname>Nao</surname><given-names>N</given-names></name><name name-style="western"><surname>Shirato</surname><given-names>K</given-names></name><name name-style="western"><surname>Ujike</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamitani</surname><given-names>W</given-names></name></person-group>, <article-title>et al</article-title>. <source>The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells</source>. <source>J Virol</source>. (<year>2020</year>) <volume>95</volume>:<fpage>e01648</fpage>&#8211;<lpage>20</lpage>. doi: <pub-id pub-id-type="doi">10.1128/jvi.01648-20</pub-id><pub-id pub-id-type="pmcid">PMC7737752</pub-id><pub-id pub-id-type="pmid">33055254</pub-id></mixed-citation></ref><ref id="ref77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stockman</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>R</given-names></name><name name-style="western"><surname>Garner</surname><given-names>P</given-names></name></person-group>. <article-title>SARS: systematic review of treatment effects</article-title>. <source>PLoS Med</source>. (<year>2006</year>) <volume>3</volume>:<fpage>1525</fpage>&#8211;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pmed.0030343</pub-id><pub-id pub-id-type="pmcid">PMC1564166</pub-id><pub-id pub-id-type="pmid">16968120</pub-id></mixed-citation></ref><ref id="ref78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name><name name-style="western"><surname>Hao</surname><given-names>G</given-names></name></person-group>. <article-title>The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease</article-title>. <source>Cardiovasc Res.</source> (<year>2020</year>) <volume>116</volume>:<fpage>1932</fpage>&#8211;<lpage>1936</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cvr/cvaa093</pub-id><pub-id pub-id-type="pmid">32267499</pub-id><pub-id pub-id-type="pmcid">PMC7184394</pub-id></mixed-citation></ref><ref id="ref79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>QQ</given-names></name><name name-style="western"><surname>Berger</surname><given-names>NA</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R</given-names></name></person-group>. <article-title>Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection</article-title>. <source>JAMA Oncol</source>. (<year>2021</year>) <volume>7</volume>:<fpage>220</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.6178</pub-id>, PMID: <pub-id pub-id-type="pmid">33300956</pub-id><pub-id pub-id-type="pmcid">PMC7729584</pub-id></mixed-citation></ref><ref id="ref80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okwan-Duodu</surname><given-names>D</given-names></name><name name-style="western"><surname>Basho</surname><given-names>R</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X</given-names></name></person-group>. <article-title>COVID-19 in cancer patients: risk, clinical features, and management</article-title>. <source>Cancer Biol Med</source>. (<year>2020</year>) <volume>17</volume>:<fpage>519</fpage>&#8211;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2020.0289</pub-id>, PMID: <pub-id pub-id-type="pmid">32944387</pub-id><pub-id pub-id-type="pmcid">PMC7476081</pub-id></mixed-citation></ref><ref id="ref81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De</surname><given-names>NN</given-names></name><name name-style="western"><surname>Moniz</surname><given-names>M</given-names></name><name name-style="western"><surname>Gama</surname><given-names>A</given-names></name><name name-style="western"><surname>Laires</surname><given-names>PA</given-names></name><name name-style="western"><surname>Goes</surname><given-names>AR</given-names></name><name name-style="western"><surname>Pedro</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Non-adherence to COVID-19 lockdown: who are they? A cross-sectional study in Portugal</article-title>. <source>Public Health</source>. (<year>2020</year>) <volume>211</volume>:<fpage>5</fpage>&#8211;<lpage>13</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.puhe.2022.07.001</pub-id><pub-id pub-id-type="pmcid">PMC9271418</pub-id><pub-id pub-id-type="pmid">35988506</pub-id></mixed-citation></ref><ref id="ref82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>G</given-names></name><name name-style="western"><surname>Shu</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Verghese</surname><given-names>D</given-names></name><name name-style="western"><surname>Uy</surname><given-names>JP</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Association between angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers use and the risk of infection and clinical outcome of COVID-19: a comprehensive systematic review and meta-analysis</article-title>. <source>medRxiv</source>. (<year>2020</year>) <fpage>20144717</fpage>. doi: <pub-id pub-id-type="doi">10.1101/2020.07.02.20144717</pub-id></mixed-citation></ref><ref id="ref83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Long</surname><given-names>C</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Q</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis</article-title>. <source>Clin Cardiol</source>. (<year>2020</year>):<fpage>1</fpage>&#8211;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1002/clc.23421</pub-id><pub-id pub-id-type="pmcid">PMC7436520</pub-id><pub-id pub-id-type="pmid">32757246</pub-id></mixed-citation></ref><ref id="ref84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Elm</surname><given-names>E</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name><name name-style="western"><surname>Pocock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>JP</given-names></name></person-group>. <article-title>STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>Lancet</source>. (<year>2007</year>) <volume>370</volume>:<fpage>1453</fpage>&#8211;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61602-X</pub-id><pub-id pub-id-type="pmid">18064739</pub-id></mixed-citation></ref><ref id="ref85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leite</surname><given-names>A</given-names></name><name name-style="western"><surname>Le&#227;o</surname><given-names>T</given-names></name><name name-style="western"><surname>Soares</surname><given-names>P</given-names></name><name name-style="western"><surname>Severo</surname><given-names>M</given-names></name><name name-style="western"><surname>Moniz</surname><given-names>M</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>A case-control study of contextual factors for SARS-CoV-2 transmission</article-title>. <source>Front Public Health</source>. (<year>2021</year>) <volume>9</volume>:<fpage>772782</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpubh.2021.772782</pub-id>, PMID: <pub-id pub-id-type="pmid">34805081</pub-id><pub-id pub-id-type="pmcid">PMC8599439</pub-id></mixed-citation></ref><ref id="ref86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manjunath</surname><given-names>R</given-names></name><name name-style="western"><surname>Gaonkar</surname><given-names>SL</given-names></name><name name-style="western"><surname>Saleh</surname><given-names>EAM</given-names></name><name name-style="western"><surname>Husain</surname><given-names>K</given-names></name></person-group>. <article-title>A comprehensive review on Covid-19 omicron (B.1.1.529) variant</article-title>. <source>Saudi J Biol Sci</source>. (<year>2022</year>) <volume>29</volume>:<fpage>103372</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.sjbs.2022.103372</pub-id><pub-id pub-id-type="pmid">35855306</pub-id><pub-id pub-id-type="pmcid">PMC9284530</pub-id></mixed-citation></ref><ref id="ref87"><label>87.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll10">Food and Drug Administration</collab></person-group>. Coronavirus (COVID-19) update: FDA Issues New Authorization for the BinaxNOW COVID-19 Ag Card Home Test. (<year>2020</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-authorization-binaxnow-covid-19-ag-card-home-test" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-authorization-binaxnow-covid-19-ag-card-home-test</ext-link></mixed-citation></ref><ref id="ref88"><label>88.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab id="coll11">European Commission</collab></person-group>. Coronavirus: commission puts forward rules on rapid antigen tests and secures 20 million tests for member states. (<year>2020</year>). Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2483" ext-link-type="uri">https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2483</ext-link></mixed-citation></ref><ref id="ref89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>C</given-names></name><name name-style="western"><surname>Shao</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name></person-group>. <article-title>Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis</article-title>. <source>Int J Infect Dis</source>. (<year>2022</year>) <volume>114</volume>:<fpage>252</fpage>&#8211;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijid.2021.11.009</pub-id>, PMID: <pub-id pub-id-type="pmid">34800687</pub-id><pub-id pub-id-type="pmcid">PMC8595975</pub-id></mixed-citation></ref><ref id="ref90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petr&#225;&#353;</surname><given-names>M</given-names></name><name name-style="western"><surname>M&#225;&#269;al&#237;k</surname><given-names>R</given-names></name><name name-style="western"><surname>Janovsk&#225;</surname><given-names>D</given-names></name><name name-style="western"><surname>&#268;elko</surname><given-names>AM</given-names></name><name name-style="western"><surname>D&#225;&#328;ov&#225;</surname><given-names>J</given-names></name><name name-style="western"><surname>Selinger</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression</article-title>. <source>BMC Med</source>. (<year>2022</year>) <volume>20</volume>:<fpage>461</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12916-022-02663-z</pub-id>, PMID: <pub-id pub-id-type="pmid">36434597</pub-id><pub-id pub-id-type="pmcid">PMC9701077</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>